

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
30 November 2006 (30.11.2006)

PCT

(10) International Publication Number
WO 2006/125640 A2

(51) International Patent Classification:
C07K 16/28 (2006.01) *A61P 35/00* (2006.01)

[DE/DE]; Karolingerstrasse 26, 82362 Weilheim i. Ob. (DE).

(21) International Application Number:
PCT/EP2006/004991

(74) Agent: **RICKER, Mathias**; Rechtsanwälte Attorneys at Law Patentanwälte, Prinzregentenstrasse 11, 80538 München (DE).

(22) International Filing Date: 24 May 2006 (24.05.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/683,772 24 May 2005 (24.05.2005) US
60/706,004 8 August 2005 (08.08.2005) US

(71) Applicant (for all designated States except US): **MORPHOSYS AG** [DE/DE]; Lena-Christ-Strasse 48, 82152 Martinsried (DE).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),

[Continued on next page]

(54) Title: GENERATION AND PROFILING OF FULLY HUMAN HUCAL GOLD®-DERIVED THERAPEUTIC ANTIBODIES SPECIFIC FOR HUMAN CD38

CDC assay with hCD38 CHO-transfectants



MOR03079
(EC₅₀: 230 pM)

chOKT10 (EC₅₀: 9.5 nM)

Neg. Ctrl. HuCAL® MAb

(57) Abstract: The present invention provides novel methods for using recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for CD38, which plays an integral role in various disorders or conditions. These methods take advantage of newly discovered antibodies and surprising properties of such antibodies, such as the ability to bind CD38 of minipig origin and the ability to induce, by cross-linking, specific killing of cells that express CD38. These antibodies as well as the novel methods for using those antibodies can be used to treat, for example, hematological malignancies such as multiple myeloma.



European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Published:

- *without international search report and to be republished upon receipt of that report*

**Generation and profiling of fully human HuCAL GOLD[®]-derived
therapeutic antibodies specific for human CD38**

5

SUMMARY OF THE INVENTION

It is an object of the present invention to provide a method of inducing specific killing of tumor cells that express CD38. In one aspect, the specific killing of tumor cells occurs by CD38 cross-linking through incubating CD38-expressing tumor cells in the presence of a sufficient amount of a human or humanized anti-CD38 antibody or a functional fragment thereof and a control antibody designated as anti-CD20 under conditions that permit cross-linking, and detecting the specific killing activity of the human or humanized anti-CD38 antibody or functional fragment thereof. Preferably, the specific killing activity of the human or humanized anti-CD38 antibody is at least 2-fold, 3-fold, 4-fold or 5-fold better than the specific killing activity of the control antibody.

It is also an object of the present invention to provide a method of inducing specific killing of tumor cells that express CD38, by CD38 cross-linking, through administering to a subject in need thereof an effective amount of a human or humanized anti-CD38 antibody or a functional fragment thereof, and detecting the specific killing activity of the human or humanized anti-CD38 antibody or the functional fragment thereof. Such tumor cells can be of human, minipig or rabbit origin.

In one aspect, the invention provides a human or humanized anti-CD38 antibody or a functional fragment thereof that can be used in a method of inducing specific killing of tumor cells. Such an antibody or functional fragment thereof may contain a variable heavy chain depicted in SEQ ID NO: 1 (DNA), 5 (protein), 2 (DNA), 6 (protein), 3 (DNA), 7 (protein) or 4 (DNA), 8 (protein); and/or a light chain depicted in SEQ ID NO: 9 (DNA), 13 (protein), 10 (DNA), 14 (protein), 11 (DNA), 15 (protein) or 12.

It is also an object of the present invention to provide a method of detecting the presence of CD38 in a tissue or a cell of minipig origin, comprising the steps of allowing a human or humanized anti-CD38 antibody or a functional fragment thereof to come into contact with CD38 and detecting the specific binding of the human or humanized anti-CD38 antibody or functional fragment thereof to the CD38, where the antibody or functional fragment thereof is also able to specifically bind to CD38 of human origin. CD38 of minipig origin may be comprised within an isolated cell type selected from the group consisting of peripheral blood monocyte, erythrocyte, lymphocyte, thymocyte, muscle cell, cerebellum cell, pancreas cell, lymph-node cell, tonsil cell, spleen cell, prostate cell, skin cell and a cell of the retina.

Such a human or humanized anti-CD38 antibody or a functional fragment thereof may contain a heavy chain depicted in SEQ ID NO: 1 (DNA), 5 (protein); and/or a light chain depicted in SEQ ID NO: 9 (DNA), 13 (protein) and may have at least 60 percent identity in the heavy chain regions depicted in SEQ ID NO: 1 (DNA),

5 (protein) and/or may have at least 60 percent identity in the light chain regions depicted in SEQ ID NO 9 (DNA), 13 (protein).

It is another object of the present invention to provide a method of detecting CD38 in a CD38-expressing erythrocyte, by allowing a human or humanized anti-
5 CD38 antibody or a functional fragment thereof to come into contact with CD38-expressing erythrocytes, and detecting the specific binding of the human or humanized anti-CD38 antibody or functional fragment thereof to the CD38-expressing erythrocytes, where the antibody or functional fragment thereof is also able to specifically bind to human CD38 from a cell or tissue other than human
10 erythrocytes. Such a cell can be a human lymphocyte. Such a human or humanized anti-CD38 antibody or functional fragment thereof may contain a heavy chain depicted in SEQ ID NO: 2 (DNA), 6 (protein) or 3 (DNA), 7 (protein); and/or a light chain depicted in SEQ ID NO: 10 (DNA), 14 (protein) or 11 (DNA), 15 (protein) and may have at least 60 percent identity in the heavy
15 chain regions depicted in SEQ ID NO 2 (DNA), 6 (protein) or 3 (DNA), 7 (protein) and at least 60 percent identity in the light chain regions depicted in SEQ ID NO: 10 (DNA), 14 (protein) or 11 (DNA), 15 (protein).

Finally, the present invention relates to a method for inducing specific killing, wherein the specific killing which occurs by CD38 cross-linking additionally is
20 caused by antibody-dependent cellular cytotoxicity and/or complement-dependent cytotoxicity

BRIEF DESCRIPTION OF THE FIGURES

Figure 1a provides nucleic acid sequences of various antibody variable heavy regions for use in the present invention.

Figure 1b provides amino acid sequences of various antibody variable heavy regions for use in the present invention. CDR regions HCDR1, HCDR2 and HCDR3 are designated from N- to C-terminus in boldface.

Figure 2a provides nucleic acid sequences of various antibody variable light regions for use in the present invention.

Figure 2b provides amino acid sequences of various antibody variable light regions for use in the present invention. CDR regions LCDR1, LCDR2 and LCDR3 are designated from N- to C-terminus in boldface.

Figure 3 provides amino acid sequences of variable heavy regions of various consensus-based HuCAL antibody master gene sequences. CDR regions HCDR1, HCDR2 and HCDR3 are designated from N- to C-terminus in boldface.

Figure 4 provides amino acid sequences of variable light regions of various consensus-based HuCAL antibody master gene sequences. CDR regions LCDR1, LCDR2 and LCDR3 are designated from N- to C-terminus in boldface.

Figure 5 provides the amino acid sequence of CD38 (SWISS-PROT primary accession number P28907).

Figure 6 provides the nucleotide sequences of the heavy and light chains of chimeric OKT10.

Figure 7 provides a schematic overview of epitopes of representative antibodies of the present invention.

Figure 8 provides the DNA sequence of pMORPH@_h_IgG1_1 (bp 601-2100) (SEQ ID NO: 32): The vector is based on the pcDNA3.1+ vectors (Invitrogen). The amino acid sequence of the VH-stuffer sequence is indicated in bold, whereas the final reading frames of the VH-leader sequence and the constant region gene are printed in non-bold. Restriction sites are indicated above the sequence. The priming sites of the sequencing primers are underlined.

Figure 9 provides the DNA sequence of Ig kappa light chain expression vector pMORPH@_h_Igκ_1 (bp 601-1400) (SEQ ID NO: 33): The vector is based on the pcDNA3.1+ vectors (Invitrogen). The amino acid sequences of the Vκ-stuffer sequence is indicated in bold, whereas the final reading frames of the Vκ-leader sequence and of the constant region gene are printed in non-bold. Restriction sites are indicated above the sequence. The priming sites of the sequencing primers are underlined.

Figure 10 provides the DNA sequence of HuCAL Ig lambda light chain vector pMORPH@_h_Igλ_1 (bp 601-1400) (SEQ ID NO: 34): The amino acid sequence of the Vλ-stuffer sequence is indicated in bold, whereas the final reading frames of the Vλ-leader sequence and of the constant region gene are printed in non-bold. Restriction sites are indicated above the sequence. The priming sites of the sequencing primers are underlined.

Figure 11: PBMCs from 4-6 different human donors (as indicated by individual dots) were incubated with MOR03077, 03079, 03080, 03100 and the chimeric OKT10. The agonistic murine monoclonal antibody IB4 and phytohemagglutinine (PHA) served as positive controls for the induction of IL-6 (panel A), IFN-γ (panel B), and proliferation -(panel C). For detection of

proliferation a standard BrdU-assay was applied and incorporation measured *via* chemiluminescence (in relative light units; RLU). IFN- γ and IL-6 release into the cell culture supernatant were analyzed according to a given standard in pg/ml (IFN- γ) or increase in RLU (IL-6) using an ELISA set-up. An irrelevant HuCAL[®] antibody served as negative control (NC).

PBMCs for proliferation assay were cultured for 3 days, PBMCs for IL-6 and IFN γ - Release Assay were cultured for 24 hours in the presence of the respective antibody(ies).

Figure 12: hCD38 Fc fusion proteins (aa 45-300 or aa 45-273) as well as the control antigens bovine serum albumine (BSA) and lysozyme were directly coated onto ELISA wells at concentrations of 5 μ g/ml followed by a blocking step and the addition of 10 μ g/ml of different anti-hCD38 antibodies as fully human or chimeric IgG1 (**A**: chOKT10, hu03077, hu03079, hu03080, hu03100) or murine IgG2a (**B**: mu03079, mu03080, mu1B4) or IgG1 isotypes (**B**: murine OKT10). Bound antibodies were detected *via* anti-human or anti-murine Fab alkaline phosphatase conjugates (Conj.) in a fluorescence-based read-out (Excitation-wavelength at 430 nm; Emission-wavelength: 535 nm).

Figure 13 provides data about the cytotoxicity towards CD34+/CD38+ progenitor cells: PBMCs from healthy donors harboring autologous CD34+/CD38+ progenitor cells were incubated with HuCAL[®] Mab#1 (=MOR03077), Mab#2 (=MOR03079), and Mab#3 (=MOR03080), the positive control (PC = chOKT10) and an irrelevant HuCAL[®] negative control for 4 hours, respectively. Afterwards, the cell suspension was mixed with conditioned methyl-cellulose medium and incubated for 2 weeks. Colony forming units (CFU) derived

from erythroid burst forming units (BFU-E; panel B) and
granulocyte/erythroid/macrophage/ megakaryocyte stem cells (CFU-GEMM;
panels B) and granulocyte/macrophage stem cells (CFU-GM; panel C) were
counted and normalized against the medium control ("none" = medium). Panel A
5 represents the total number of CFU (Total CFUc) for all progenitors. Mean values
from at least 10 different PBMC donors are given. Error bars represent standard
error of the mean.

Figure 14 provides data about ADCC with different cell-lines:

- a: Single measurements (except for RPMI8226: average from 4 indiv.
10 Assays); E:T -ratio: 30:1
- b: Namba et al., 1989
- c: 5 µg/ml used for antibody conc. (except for Raji with 0.1 µg/ml)
- d: addition of retinoic assay for stimulation of CD38-expression
specific killing [%] = [(exp. killing - medium killing) / (1 -
15 medium killing)] * 100
- PC: Positive control (=chOKT10)
- MM: Multiple myeloma
- CLL: Chronic B-cell leukemia
- ALL: Acute lymphoblastic leukemia
- 20 AML: Acute myeloid leukemia
- DSMZ: Deutsche Sammlung für Mikroorganismen und
Zellkulturen GmbH
- ATCC: American type culture collection

ECACC: European collection of cell cultures

MFI: Mean fluorescence intensities.

Figure 15 provides data about ADCC with MM-samples:

^a: 2-4 individual analyses

- 5 Figure 16 provides the experimental results of mean tumor volumes after treatment of human myeloma xenograft with MOR03080: group 1: vehicle; group 2: MOR03080 as hIgG1 1mg/kg 32-68 days every second day; group 3: MOR03080 as hIgG1 5 mg/kg 32-68 days every second day; group 4: MOR03080 as chIgG2a 5 mg/kg 32-68 days every second day; group 5: MOR03080 as hIgG1 1 mg/kg, 14-36 days every second day; group 6: untreated.
- 10

Figure 17 provides FACS analysis of cross-reactivity of anti-CD38 antibodies with different animal species.

Figure 18 provides CD38 cross-linking with Raji cells.

Figure 19: CDC assay with hCD38 CHO transfectants

- 15 CHO cells stably transfected with hCD38 were incubated with MOR03079 hIgG1, chimeric OKT10 (chOKT10) or an irrelevant HuCAL[®] IgG1 as negative control in the presence of human serum (source of complement). The negative control is represented by the highest antibody concentration used. Error bars represent the standard deviation based on three individual measurements for each antibody concentration. EC₅₀ values were calculated appropriately.
- 20

Figure 20: ADCC assay with primary multiple myeloma samples

Human PBMCs (Effectors) and cells from the bone marrow aspirates of several MM-patients (MM-sample #6,7,10,11,12,14) were mixed at an E:T-ratio

of 30:1. Serial dilutions were applied for the human IgG1 MAbs (MOR03077, MOR03079, MOR03080) or the chimeric OKT10 (chOKT10) whereas the irrelevant negative control antibody (HuCAL[®] MAb, NC) antibody as well as MOR03079 (MM#10 and #11) is represented by the highest antibody concentration used. Error bars represent standard deviations based on three individual measurements for each antibody concentration. Sample MM#14 was derived from a plasma cell leukemia patient.

10

DETAILED DESCRIPTION OF THE INVENTION

The present invention is based on the discovery of novel methods of using antibodies that are specific to or have a high affinity for CD38 and can deliver a therapeutic benefit to a subject. The antibodies, which may be human or humanized, can be used in many contexts, which are more fully described herein. Suitable antibodies for use in the present invention are disclosed in US 60/614,471, which hereby is incorporated by reference.

A “human” antibody or functional human antibody fragment is hereby defined as one that is not chimeric (*e.g.*, not “humanized”) and not from (either in whole or in part) a non-human species. A human antibody or functional antibody fragment can be derived from a human or can be a synthetic human antibody. A “synthetic human antibody” is defined herein as an antibody having a sequence derived, in whole or in part, *in silico* from synthetic sequences that are based on the analysis of known human antibody sequences. *In silico* design of a human

antibody sequence or fragment thereof can be achieved, for example, by analyzing a database of human antibody or antibody fragment sequences and devising a polypeptide sequence utilizing the data obtained therefrom. Another example of a human antibody or functional antibody fragment, is one that is encoded by a nucleic acid isolated from a library of antibody sequences of human origin (*i.e.*, such library being based on antibodies taken from a human natural source).

A “humanized antibody” or functional humanized antibody fragment is defined herein as one that is (i) derived from a non-human source (*e.g.*, a transgenic mouse which bears a heterologous immune system), which antibody is based on a human germline sequence; or (ii) chimeric, wherein the variable domain is derived from a non-human origin and the constant domain is derived from a human origin or (iii) CDR-grafted, wherein the CDRs of the variable domain are from a non-human origin, while one or more frameworks of the variable domain are of human origin and the constant domain (if any) is of human origin.

As used herein, an antibody “binds specifically to,” is “specific to/for” or “specifically recognizes” an antigen (here, CD38) if such antibody is able to discriminate between such antigen and one or more reference antigen(s), since binding specificity is not an absolute, but a relative property. In its most general form (and when no defined reference is mentioned), “specific binding” is referring to the ability of the antibody to discriminate between the antigen of interest and an unrelated antigen, as determined, for example, in accordance with one of the following methods. Such methods comprise, but are not limited to Western blots, ELISA-, RIA-, ECL-, IRMA-tests, FACS, IHC and peptide scans. For example, a

standard ELISA assay can be carried out. The scoring may be carried out by standard color development (*e.g.* secondary antibody with horseradish peroxidase and tetramethyl benzidine with hydrogenperoxide). The reaction in certain wells is scored by the optical density, for example, at 450 nm. Typical background
5 (=negative reaction) may be 0.1 OD; typical positive reaction may be 1 OD. This means the difference positive/negative can be more than 10-fold. Typically, determination of binding specificity is performed by using not a single reference antigen, but a set of about three to five unrelated antigens, such as milk powder, BSA, transferrin or the like. It is possible for an antibody to be “specific to” or
10 “specific for” an antigen of 2 or more cells/tissues and/or 2 or more species, provided that the antibody meets binding criteria for each of such cells/tissues and species, for example. Accordingly, an antibody may bind specifically to the target antigen CD38 on various cell types and/or tissues, *e.g.* erythrocytes, lymphocytes isolated from peripheral blood, spleen or lymph-nodes. In addition, an antibody
15 may be specific to both CD38 of one species and CD38 of another species.

“Specific binding” also may refer to the ability of an antibody to discriminate between the target antigen and one or more closely related antigen(s), which are used as reference points, *e.g.* between CD38 and CD157. Additionally, “specific binding” may relate to the ability of an antibody to discriminate between
20 different parts of its target antigen, *e.g.* different domains or regions of CD38, such as epitopes in the N-terminal or in the C-terminal region of CD38, or between one or more key amino acid residues or stretches of amino acid residues of CD38.

Also, as used herein, an “immunoglobulin” (Ig) hereby is defined as a protein belonging to the class IgG, IgM, IgE, IgA, or IgD (or any subclass thereof), and includes all conventionally known antibodies and functional fragments thereof. A “functional fragment” of an antibody/immunoglobulin hereby is defined as a fragment of an antibody/immunoglobulin (*e.g.*, a variable region of an IgG) that retains the antigen-binding region. An “antigen-binding region” of an antibody typically is found in one or more hypervariable region(s) of an antibody, *i.e.*, the CDR-1, -2, and/or -3 regions; however, the variable “framework” regions can also play an important role in antigen binding, such as by providing a scaffold for the CDRs. Preferably, the “antigen-binding region” comprises at least amino acid residues 4 to 103 of the variable light (VL) chain and 5 to 109 of the variable heavy (VH) chain, more preferably amino acid residues 3 to 107 of VL and 4 to 111 of VH, and particularly preferred are the complete VL and VH chains (amino acid positions 1 to 109 of VL and 1 to 113 of VH; numbering according to WO 97/08320). A preferred class of immunoglobulins for use in the present invention is IgG. “Functional fragments” of the invention include the domain of a F(ab')₂ fragment, a Fab fragment and scFv. The F(ab')₂ or Fab may be engineered to minimize or completely remove the intermolecular disulphide interactions that occur between the C_{H1} and C_L domains.

An antibody for use in the invention may be derived from a recombinant antibody library that is based on amino acid sequences that have been designed *in silico* and encoded by nucleic acids that are synthetically created. *In silico* design of an antibody sequence is achieved, for example, by analyzing a database of

human sequences and devising a polypeptide sequence utilizing the data obtained therefrom. Methods for designing and obtaining *in silico*-created sequences are described, for example, in Knappik *et al.*, J. Mol. Biol. (2000) 296:57; Krebs *et al.*, J. Immunol. Methods. (2001) 254:67; and U.S. Patent No. 6,300,064 issued to
5 Knappik *et al.*, which hereby are incorporated by reference in their entirety.

Antibodies for Use in the Invention

Throughout this document, reference is made to the following representative antibodies for use in the invention: "antibody nos." or "LACS" or "MOR" 3077 or 03077 (MAb#1), 3079 or 03079 (MAb#2), 3080 or 03080 (MAb#3) and 3100 or
10 03100 (MAb#4). LAC 3077 represents an antibody having a variable heavy region corresponding to SEQ ID NO: 1 (DNA)/SEQ ID NO: 5 (protein) and a variable light region corresponding to SEQ ID NO: 9 (DNA)/SEQ ID NO: 13 (protein). LAC 3079 represents an antibody having a variable heavy region corresponding to SEQ ID NO: 2 (DNA)/SEQ ID NO: 6 (protein) and a variable
15 light region corresponding to SEQ ID NO: 10 (DNA)/SEQ ID NO: 14 (protein). LAC 3080 represents an antibody having a variable heavy region corresponding to SEQ ID NO: 3 (DNA)/SEQ ID NO: 7 (protein) and a variable light region corresponding to SEQ ID NO: 11 (DNA)/SEQ ID NO: 15 (protein). LAC 3100 represents an antibody having a variable heavy region corresponding to SEQ ID
20 NO: 4 (DNA)/SEQ ID NO: 8 (protein) and a variable light region corresponding to SEQ ID NO: 12 (DNA)/SEQ ID NO: 16 (protein).

In one aspect, the invention provides methods for using antibodies having an antigen-binding region that can bind specifically to or has a high affinity for one or more regions of CD38, whose amino acid sequence is depicted by SEQ ID NO:

22. An antibody is said to have a “high affinity” for an antigen if the affinity measurement is at least 100 nM (monovalent affinity of Fab fragment). An antibody or antigen-binding region for use in the present invention preferably can bind to CD38 with an affinity of about less than 100 nM, more preferably less than about 60 nM, and still more preferably less than about 30 nM. Further preferred are uses of antibodies that bind to CD38 with an affinity of less than about 10 nM, and more preferably less than 3 about nM. For instance, the affinity of an antibody for use in the invention against CD38 may be about 10.0 nM or 2.4 nM (monovalent affinity of Fab fragment).

10

Specificity

The four representative antibodies were tested as human IgG1 and human-mouse chimeric IgG2a (except for MOR03100) on a panel of different antigens including two hCD38 Fc fusion (aa 45-300 & aa 45-273), BSA and lysozyme.

15 All hCD38-specific antibodies recognized only the “full-length” hCD38 Fc-fusion protein (aa 45-300) (Fig. 12), when tested with such full-length protein and a format having a C-terminally deleted format, most likely due to misfolding and loss of antigenic sites

20 Table 1 provides a summary of affinities of representative antibodies, as determined by surface plasmon resonance (Biacore) and FACS Scatchard analysis:

Table 1: Antibody Affinities

Antibody (Fab or IgG1)	BIACORE (Fab) K_D [nM]^a	FACS Scatchard (IgG1)^b K_D [nM]^a
MOR03077	56.0	0.89
MOR03079	2.4	0.60
MOR03080	27.5	0.47
MOR03100	10.0	6.31
Chimeric OKT10	not determined	8.28

^a: mean from at least 2 different affinity determinations^b: RPMI8226 MM cell-line used for FACS-Scatchards

5

With reference to Table 1, the affinity of LACs 3077, 3079, 3080 and 3100 was measured by surface plasmon resonance (Biacore) on immobilized recombinant CD38 and by a flow cytometry procedure utilizing the CD38-expressing human RPMI8226 cell line. The Biacore studies were performed on directly immobilized antigen (CD38-Fc fusion protein). The Fab format of LACs 3077, 3079, 3080 and 3100 exhibit an monovalent affinity range between about 2.4 and 56 nM on immobilized CD38-Fc fusion protein with LAC 3079 showing the highest affinity, followed by Fabs 3100, 3080 and 3077.

The IgG1 format was used for the cell-based affinity determination (FACS Scatchard). The right column of Table 1 denotes the binding strength of the

LACS in this format. LAC 3080 showed the strongest binding, which is slightly stronger than LACS 3079 and 3077.

Another preferred feature of preferred antibodies for use in the invention is their specificity for an area within the N-terminal region of CD38. For example,
5 LACs 3077, 3079, 3080, and 3100 of the invention can bind specifically to the N-terminal region of CD38.

The type of epitope to which an antibody for use in the invention binds may be linear (i.e. one consecutive stretch of amino acids) or conformational (i.e. multiple stretches of amino acids). In order to determine whether the epitope of a
10 particular antibody is linear or conformational, the skilled worker can analyze the binding of antibodies to overlapping peptides (*e.g.*, 13-mer peptides with an overlap of 11 amino acids) covering different domains of CD38. LACS 3077, 3080, and 3100 recognize discontinuous epitopes in the N-terminal region of CD38, whereas the epitope of LAC 3079 can be described as linear (see Figure 7).
15 Combined with the knowledge provided herein, the skilled worker in the art will know how to use one or more isolated epitopes of CD38 for generating antibodies having an antigen-binding region that is specific for said epitopes (*e.g.* using synthetic peptides of epitopes of CD38 or cells expressing epitopes of CD38).

An antibody for use in the invention preferably is species cross-reactive with
20 humans and at least one other non-human species. The non-human species can be non-human primate, *e.g.* rhesus, baboon and/or cynomolgus. Other non-human species can be minipig, rabbit, mouse, rat and/or hamster. An antibody that is cross reactive with at least one other species beside human can provide greater flexibility and benefits over known anti-CD38 antibodies, for purposes of

conducting *in vivo* studies in multiple species with the same antibody. An antibody that is cross reactive with minipig and/or rabbit, for example, can be a candidate for toxicology and safety studies.

Preferably, an antibody for use in the invention not only is able to bind to CD38, but also is able to mediate killing of a cell expressing CD38. More specifically, an antibody for use in the invention can mediate its therapeutic effect by depleting CD38-positive (*e.g.*, malignant) cells via antibody-effector functions. These functions include antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).

Table 2 provides a summary of the determination of EC50 values of representative antibodies of the invention in both ADCC and CDC:

Table 2: EC50 Values of Antibodies

Antibody (IgG1)	ADCC		CDC
	EC50 [nM]		EC50 [nM]
	LP-1	RPMI8226	CHO-transfectants
MOR03077	0.60a	0.08a	0.8c; 0.94d
MOR03079	0.09 ^a	0.04 ^a	0.41 ^c
MOR03080	0.17 ^b	0.05 ^a	3.2 ^c ; 2.93 ^d
MOR03100	1.00 ^b	0.28 ^a	10.9 ^c ; 13.61 ^c
Chimeric OKT10	5.23 ^a	4.10 ^a	9.30 ^c

^a: mean from at least 2 EC50 determinations

- ^b: single determination
- ^c: mean from 2 EC50 determinations
- ^d: mean from 3 EC50 determinations
- ^e: mean from 4 EC50 determinations

5

CD38-expression, however, is not only found on immune cells within the myeloid (*e.g.* monocytes, granulocytes) and lymphoid lineage (*e.g.* activated B and T-cells; plasma cells), but also on the respective precursor cells. Since it is important that those cells are not affected by antibody-mediated killing of malignant cells, the antibodies of the present invention are preferably not cytotoxic to precursor cells.

In addition to its catalytic activities as a cyclic ADP-ribose cyclase and hydrolase, CD38 displays the ability to transduce signals of biological relevance (Hoshino *et al.*, 1997; Ausiello *et al.*, 2000). Those functions can be induced *in vivo* by, *e.g.* receptor-ligand interactions or by cross-linking with agonistic anti-CD38 antibodies, leading, *e.g.* to calcium mobilization, lymphocyte proliferation and release of cytokines. Preferably, the antibodies of the present invention are non-agonistic antibodies.

Peptide Variants

Antibodies for use in the invention are not limited to the specific peptide sequences provided herein. Rather, the invention also embodies the use of variants of these polypeptides. With reference to the instant disclosure and conventionally available technologies and references, the skilled worker will be able to prepare, test and utilize functional variants of the antibodies disclosed herein, while appreciating that variants having the ability to mediate killing of a CD38+ target cell fall within the scope of the present invention. As used in this

context, “ability to mediate killing of a CD38+ target cell” means a functional characteristic ascribed to an anti-CD38 antibody for use in the invention. Ability to mediate killing of a CD38+ target cell, thus, includes the ability to mediate killing of a CD38+ target cell, *e.g.* by ADCC and/or CDC, or by toxin constructs
5 conjugated to an antibody for use in the invention.

A variant can include, for example, an antibody that has at least one altered complementarity determining region (CDR) (hyper-variable) and/or framework (FR) (variable) domain/position, vis-à-vis a peptide sequence disclosed herein. To better illustrate this concept, a brief description of antibody structure follows.

10 An antibody is composed of two peptide chains, each containing one (light chain) or three (heavy chain) constant domains and a variable region (VL, VH), the latter of which is in each case made up of four FR regions and three interspaced CDRs. The antigen-binding site is formed by one or more CDRs, yet the FR regions provide the structural framework for the CDRs and, hence, play an
15 important role in antigen binding. By altering one or more amino acid residues in a CDR or FR region, the skilled worker routinely can generate mutated or diversified antibody sequences, which can be screened against the antigen, for new or improved properties, for example.

Tables 3a (VH) and 3b (VL) delineate the CDR and FR regions for certain
20 antibodies for use in the invention and compare amino acids at a given position to each other and to corresponding consensus or “master gene” sequences (as described in U.S. Patent No. 6,300,064):

Table 3a: VH Sequences

VH		VH sequences CD38 binders																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																					
		Framework 1												Framework 2																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																									
		3												4												5												6																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																	
		CDR1												CDR2												CDR3												CDR4																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																	
Position		1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100	101	102	103	104	105	106	107	108	109	110	111	112	113	114	115	116	117	118	119	120	121	122	123	124	125	126	127	128	129	130	131	132	133	134	135	136	137	138	139	140	141	142	143	144	145	146	147	148	149	150	151	152	153	154	155	156	157	158	159	160	161	162	163	164	165	166	167	168	169	170	171	172	173	174	175	176	177	178	179	180	181	182	183	184	185	186	187	188	189	190	191	192	193	194	195	196	197	198	199	200	201	202	203	204	205	206	207	208	209	210	211	212	213	214	215	216	217	218	219	220	221	222	223	224	225	226	227	228	229	230	231	232	233	234	235	236	237	238	239	240	241	242	243	244	245	246	247	248	249	250	251	252	253	254	255	256	257	258	259	260	261	262	263	264	265	266	267	268	269	270	271	272	273	274	275	276	277	278	279	280	281	282	283	284	285	286	287	288	289	290	291	292	293	294	295	296	297	298	299	300	301	302	303	304	305	306	307	308	309	310	311	312	313	314	315	316	317	318	319	320	321	322	323	324	325	326	327	328	329	330	331	332	333	334	335	336	337	338	339	340	341	342	343	344	345	346	347	348	349	350	351	352	353	354	355	356	357	358	359	360	361	362	363	364	365	366	367	368	369	370	371	372	373	374	375	376	377	378	379	380	381	382	383	384	385	386	387	388	389	390	391	392	393	394	395	396	397	398	399	400	401	402	403	404	405	406	407	408	409	410	411	412	413	414	415	416	417	418	419	420	421	422	423	424	425	426	427	428	429	430	431	432	433	434	435	436	437	438	439	440	441	442	443	444	445	446	447	448	449	450	451	452	453	454	455	456	457	458	459	460	461	462	463	464	465	466	467	468	469	470	471	472	473	474	475	476	477	478	479	480	481	482	483	484	485	486	487	488	489	490	491	492	493	494	495	496	497	498	499	500	501	502	503	504	505	506	507	508	509	510	511	512	513	514	515	516	517	518	519	520	521	522	523	524	525	526	527	528	529	530	531	532	533	534	535	536	537	538	539	540	541	542	543	544	545	546	547	548	549	550	551	552	553	554	555	556	557	558	559	560	561	562	563	564	565	566	567	568	569	570	571	572	573	574	575	576	577	578	579	580	581	582	583	584	585	586	587	588	589	590	591	592	593	594	595	596	597	598	599	600	601	602	603	604	605	606	607	608	609	610	611	612	613	614	615	616	617	618	619	620	621	622	623	624	625	626	627	628	629	630	631	632	633	634	635	636	637	638	639	640	641	642	643	644	645	646	647	648	649	650	651	652	653	654	655	656	657	658	659	660	661	662	663	664	665	666	667	668	669	670	671	672	673	674	675	676	677	678	679	680	681	682	683	684	685	686	687	688	689	690	691	692	693	694	695	696	697	698	699	700	701	702	703	704	705	706	707	708	709	710	711	712	713	714	715	716	717	718	719	720	721	722	723	724	725	726	727	728	729	730	731	732	733	734	735	736	737	738	739	740	741	742	743	744	745	746	747	748	749	750	751	752	753	754	755	756	757	758	759	760	761	762	763	764	765	766	767	768	769	770	771	772	773	774	775	776	777	778	779	780	781	782	783	784	785	786	787	788	789	790	791	792	793	794	795	796	797	798	799	800	801	802	803	804	805	806	807	808	809	810	811	812	813	814	815	816	817	818	819	820	821	822	823	824	825	826	827	828	829	830	831	832	833	834	835	836	837	838	839	840	841	842	843	844	845	846	847	848	849	850	851	852	853	854	855	856	857	858	859	860	861	862	863	864	865	866	867	868	869	870	871	872	873	874	875	876	877	878	879	880	881	882	883	884	885	886	887	888	889	890	891	892	893	894	895	896	897	898	899	900	901	902	903	904	905	906	907	908	909	910	911	912	913	914	915	916	917	918	919	920	921	922	923	924	925	926	927	928	929	930	931	932	933	934	935	936	937	938	939	940	941	942	943	944	945	946	947	948	949	950	951	952	953	954	955	956	957	958	959	960	961	962	963	964	965	966	967	968	969	970	971	972	973	974	975	976	977	978	979	980	981	982	983	984	985	986	987	988	989	990	991	992	993	994	995	996	997	998	999	1000	1001	1002	1003	1004	1005	1006	1007	1008	1009	1010	1011	1012	1013	1014	1015	1016	1017	1018	1019	1020	1021	1022	1023	1024	1025	1026	1027	1028	1029	1030	1031	1032	1033	1034	1035	1036	1037	1038	1039	1040	1041	1042	1043	1044	1045	1046	1047	1048	1049	1050	1051	1052	1053	1054	1055	1056	1057	1058	1059	1060	1061	1062	1063	1064	1065	1066	1067	1068	1069	1070	1071	1072	1073	1074	1075	1076	1077	1078	1079	1080	1081	1082	1083	1084	1085	1086	1087	1088	1089	1090	1091	1092	1093	1094	1095	1096	1097	1098	1099	1100	1101	1102	1103	1104	1105	1106	1107	1108	1109	1110	1111	1112	1113	1114	1115	1116	1117	1118	1119	1120	1121	1122	1123	1124	1125	1126	1127	1128	1129	1130	1131	1132	1133	1134	1135	1136	1137	1138	1139	1140	1141	1142	1143	1144	1145	1146	1147	1148	1149	1150	1151	1152	1153	1154	1155	1156	1157	1158	1159	1160	1161	1162	1163	1164	1165	1166	1167	1168	1169	1170	1171	1172	1173	1174	1175	1176	1177	1178	1179	1180	1181	1182	1183	1184	1185	1186	1187	1188	1189	1190	1191	1192	1193	1194	1195	1196	1197	1198	1199	1200	1201	1202	1203	1204	1205	1206	1207	1208	1209	1210	1211	1212	1213	1214	1215	1216	1217	1218	1219	1220	1221	1222	1223	1224	1225	1226	1227	1228	1229	1230	1231	1232	1233	1234	1235	1236	1237	1238	1239	1240	1241	1242	1243	1244	1245	1246	1247	1248	1249	1250	1251	1252	1253	1254	1255	1256	1257	1258	1259	1260	1261	1262	1263	1264	1265	1266	1267	1268	1269	1270	1271	1272	1273	1274	1275	1276	1277	1278	1279	1280	1281	1282	1283	1284	1285	1286	1287	1288	1289	1290	1291	1292	1293	1294	1295	1296	1297	1298	1299	1300	1301	1302	1303	1304	1305	1306	1307	1308	1309	1310	1311	1312	1313	1314	1315	1316	1317	1318	1319	1320	1321	1322	1323	1324	1325	1326	1327	1328	1329	1330	1331	1332	1333	1334	1335	1336	1337	1338	1339	1340	1341	1342	1343	1344	1345	1346	1347	1348	1349	1350	1351	1352	1353	1354	1355	1356	1357	1358	1359	1360	1361	1362	1363	1364	1365	1366	1367	1368	1369	1370	1371	1372	1373	1374	1375	1376	1377	1378	1379	1380	1381	1382	1383	1384	1385	1386	1387	1388	1389	1390	1391	1392	1393	1394	1395	1396	1397	1398	1399	1400	1401	1402	1403	1404	1405	1406	1407	1408	1409	1410	1411	1412	1413	1414	1415	1416	1417	1418	1419	1420	1421	1422	1423	1424	1425	1426	1427	1428	1429	1430	1431	1432	1433	1434	1435	1436	1437	1438	1439	1440	1441	1442	1443	1444	1445	1446	1447	1448	1449	1450	1451	1452	1453	1454	1455	1456	1457	1458	1459	1460	1461	1462	1463	1464	1465	1466	1467	1468	1469	1470	1471	1472	1473	1474	1475	1476	1477	1478

Table 3a continued

VH

		Framework 3										CDR 3										Framework 4																																																																																																													
		8										10										11																																																																																																													
Position		7										9										10										11																																																																																																			
		9 0 1 2 3 4 5 6 7 8 9 0 1 2 a b c 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 a b c d e f g h i j 1 2 3 4 5 6 7 8 9 0 1 2 3										Bsh-III										Syt										Bpl																																																																																																			
												EagI																																																																																																																							

VL sequences CD38 binders

22

Table 3b continued

		Framework 3										CDR3										Framework 4																																																	
		7										8										9										10																																							
Position		8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9																																						
												BstI																				HpaI										MscI																													
												E D										C Q Q H Y T T P										P										V F G G G T K L T V L G																													
VL3	SEQ ID NO 19	G N T A T L T I S G T Q A										E D										E A D Y Y C										Q Q H Y T T P										P										V F G G G T K L T V L G																			
3080	SEQ ID NO 15	G N T A T L T I S G T Q A										E D										E A D Y Y C										S S Y D S S Y T										F										V F G G G T K L T V L G																			
3100	SEQ ID NO 16	G N T A T L T I S G T Q A										E D										E A D Y Y C										Q S Y D Y L H D F										F										V F G G G T K L T V L G																			
																						1										1										1										1																			
VL4	SEQ ID NO 20	G T D F T L T I S S L Q										P E D										F A T Y Y C										Q Q H Y T T P										P										T F G G G T K V E I K R																			
3079	SEQ ID NO 14	G T D F T L T I S S L Q										P E D										F A T Y Y C										Q Q A Y S G S										I										T F G G G T K V E I K R T																			
																																1										1										1										1									
VL42	SEQ ID NO 21	G T D F T L K I S R V E										A E D										V G V Y Y C										Q Q H Y T T P										P										T F G G G T K L E I K R																			
3077	SEQ ID NO 13	G T D F T L K I S R V E										A E D										V G V Y Y C										Q Q V S S K S										A										T F G G G T K V E I K R T																			
																																1										1										1										1									

The skilled worker can use the data in Tables 3a and 3b to design peptide variants, the use of which is within the scope of the present invention. It is preferred that variants are constructed by changing amino acids within one or more CDR regions; a variant might also have one or more altered framework regions. With reference to a comparison of the antibodies to each other, candidate residues that can be changed include *e.g.* residues 4 or 37 of the variable light and *e.g.* residues 13 or 43 of the variable heavy chains of LACs 3080 and 3077, since these are positions of variance vis-à-vis each other. Alterations also may be made in the framework regions. For example, a peptide FR domain might be altered where there is a deviation in a residue compared to a germline sequence.

With reference to a comparison of the antibodies to the corresponding consensus or “master gene” sequence, candidate residues that can be changed include *e.g.* residues 27, 50 or 90 of the variable light chain of LAC 3080 compared to VL λ 3 and *e.g.* residues 33, 52 and 97 of the variable heavy chain of LAC 3080 compared to VH3. Alternatively, the skilled worker could make the same analysis by comparing the amino acid sequences disclosed herein to known sequences of the same class of such antibodies, using, for example, the procedure described by Knappik *et al.*, 2000 and U.S. Patent No. 6,300,064 issued to Knappik *et al.*

Furthermore, variants may be obtained by using one LAC as starting point for optimization by diversifying one or more amino acid residues in the LAC, preferably amino acid residues in one or more CDRs, and by screening the resulting collection of antibody variants for variants with improved properties. Particularly preferred is diversification of one or more amino acid residues in CDR-3 of VL, CDR-3 of VH, CDR-1 of VL and/or CDR-2 of VH. Diversification can be done by synthesizing a collection of DNA molecules using trinucleotide mutagenesis (TRIM) technology (Virnekäs, B., Ge, L., Plückthun, A., Schneider, K.C., Wellnhofer, G., and Moroney S.E. (1994) Trinucleotide

phosphoramidites: ideal reagents for the synthesis of mixed oligonucleotides for random mutagenesis. Nucl. Acids Res. 22, 5600.).

Conservative Amino Acid Variants

Polypeptide variants may be made that conserve the overall molecular structure of an antibody peptide sequence described herein. Given the properties of the individual amino acids, some rational substitutions will be recognized by the skilled worker. Amino acid substitutions, *i.e.*, "conservative substitutions," may be made, for instance, on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues involved.

For example, (a) nonpolar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan, and methionine; (b) polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamine; (c) positively charged (basic) amino acids include arginine, lysine, and histidine; and (d) negatively charged (acidic) amino acids include aspartic acid and glutamic acid. Substitutions typically may be made within groups (a)-(d). In addition, glycine and proline may be substituted for one another based on their ability to disrupt α -helices. Similarly, certain amino acids, such as alanine, cysteine, leucine, methionine, glutamic acid, glutamine, histidine and lysine are more commonly found in α -helices, while valine, isoleucine, phenylalanine, tyrosine, tryptophan and threonine are more commonly found in β -pleated sheets. Glycine, serine, aspartic acid, asparagine, and proline are commonly found in turns. Some preferred substitutions may be made among the following groups: (i) S and T; (ii) P and G; and (iii) A, V, L and I. Given the known genetic code, and recombinant and synthetic DNA techniques, the skilled scientist readily can construct DNAs encoding the conservative amino acid variants. In one particular example, amino acid position 3 in SEQ ID NOS: 5, 6, 7, and/or 8 can be changed from a Q to an E.

As used herein, "sequence identity" between two polypeptide sequences indicates the percentage of amino acids that are identical between the sequences. "Sequence similarity" indicates the percentage of amino acids that either are identical or that represent conservative amino acid substitutions. Preferred polypeptide sequences of the invention have a sequence identity in the CDR regions of at least 60%, more preferably, at least 70% or 80%, still more preferably at least 90% and most preferably at least 95%. Preferred antibodies also have a sequence similarity in the CDR regions of at least 80%, more preferably 90% and most preferably 95%.

DNA molecules of the invention

The present invention also relates to uses of DNA molecules that encode an antibody for use in the invention. These sequences include, but are not limited to, those DNA molecules set forth in Figures 1a and 2a.

DNA molecules of the invention are not limited to the sequences disclosed herein, but also include variants thereof. DNA variants within the invention may be described by reference to their physical properties in hybridization. The skilled worker will recognize that DNA can be used to identify its complement and, since DNA is double stranded, its equivalent or homolog, using nucleic acid hybridization techniques. It also will be recognized that hybridization can occur with less than 100% complementarity. However, given appropriate choice of conditions, hybridization techniques can be used to differentiate among DNA sequences based on their structural relatedness to a particular probe. For guidance regarding such conditions see, Sambrook et al., 1989 (Sambrook, J., Fritsch, E. F. and Maniatis, T. (1989) *Molecular Cloning: A laboratory manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, USA) and Ausubel et al., 1995 (Ausubel, F. M., Brent, R., Kingston, R. E., Moore, D. D., Sedman, J. G., Smith, J. A., & Struhl, K. eds. (1995). *Current Protocols in Molecular Biology*. New York: John Wiley and Sons).

Structural similarity between two polynucleotide sequences can be expressed as a function of "stringency" of the conditions under which the two sequences will hybridize with one another. As used herein, the term "stringency" refers to the extent that the conditions disfavor hybridization. Stringent conditions strongly disfavor hybridization, and only the most structurally related molecules will hybridize to one another under such conditions. Conversely, non-stringent conditions favor hybridization of molecules displaying a lesser degree of structural relatedness. Hybridization stringency, therefore, directly correlates with the structural relationships of two nucleic acid sequences. The following relationships are useful in correlating hybridization and relatedness (where T_m is the melting temperature of a nucleic acid duplex):

- a. $T_m = 69.3 + 0.41(G+C)\%$
- b. The T_m of a duplex DNA decreases by 1°C with every increase of 1% in the number of mismatched base pairs.
- c. $(T_m)_{\mu 2} - (T_m)_{\mu 1} = 18.5 \log_{10} \mu 2 / \mu 1$
where $\mu 1$ and $\mu 2$ are the ionic strengths of two solutions.

Hybridization stringency is a function of many factors, including overall DNA concentration, ionic strength, temperature, probe size and the presence of agents which disrupt hydrogen bonding. Factors promoting hybridization include high DNA concentrations, high ionic strengths, low temperatures, longer probe size and the absence of agents that disrupt hydrogen bonding. Hybridization typically is performed in two phases: the "binding" phase and the "washing" phase.

First, in the binding phase, the probe is bound to the target under conditions favoring hybridization. Stringency is usually controlled at this stage by altering the temperature. For high stringency, the temperature is usually between 65°C and 70°C , unless short (< 20 nt) oligonucleotide probes are used. A representative hybridization solution comprises 6X SSC, 0.5% SDS, 5X Denhardt's solution and 100 μg of nonspecific carrier DNA. See

Ausubel *et al.*, section 2.9, supplement 27 (1994). Of course, many different, yet functionally equivalent, buffer conditions are known. Where the degree of relatedness is lower, a lower temperature may be chosen. Low stringency binding temperatures are between about 25°C and 40°C. Medium stringency is between at least about 40°C to less than about 65°C. High stringency is at least about 65°C.

Second, the excess probe is removed by washing. It is at this phase that more stringent conditions usually are applied. Hence, it is this "washing" stage that is most important in determining relatedness via hybridization. Washing solutions typically contain lower salt concentrations. One exemplary medium stringency solution contains 2X SSC and 0.1% SDS. A high stringency wash solution contains the equivalent (in ionic strength) of less than about 0.2X SSC, with a preferred stringent solution containing about 0.1X SSC. The temperatures associated with various stringencies are the same as discussed above for "binding." The washing solution also typically is replaced a number of times during washing. For example, typical high stringency washing conditions comprise washing twice for 30 minutes at 55° C. and three times for 15 minutes at 60° C.

Accordingly, the present invention includes the use of nucleic acid molecules that hybridize to the molecules of set forth in Figures 1a and 2a under high stringency binding and washing conditions, where such nucleic molecules encode an antibody or functional fragment thereof for uses as described herein. Preferred molecules (from an mRNA perspective) are those that have at least 75% or 80% (preferably at least 85%, more preferably at least 90% and most preferably at least 95%) homology or sequence identity with one of the DNA molecules described herein. In one particular example of a variant of the invention, nucleic acid position 7 in SEQ ID NOS: 1, 2, 3 and/or 4 can be substituted from a C to a G, thereby changing the codon from CAA to GAA.

Functionally Equivalent Variants

Yet another class of DNA variants the use of which is within the scope of the invention may be described with reference to the product they encode (see the peptides listed in figures 1b and 2b). These functionally equivalent genes are characterized by the fact that they encode the same peptide sequences found in figures 1b and 2b due to the degeneracy of the genetic code. SEQ ID NOS: 1 and 31 are an example of functionally equivalent variants, as their nucleic acid sequences are different, yet they encode the same polypeptide, i.e. SEQ ID NO: 5.

It is recognized that variants of DNA molecules provided herein can be constructed in several different ways. For example, they may be constructed as completely synthetic DNAs. Methods of efficiently synthesizing oligonucleotides in the range of 20 to about 150 nucleotides are widely available. See Ausubel *et al.*, section 2.11, Supplement 21 (1993). Overlapping oligonucleotides may be synthesized and assembled in a fashion first reported by Khorana *et al.*, J. Mol. Biol. 72:209-217 (1971); see also Ausubel *et al.*, *supra*, Section 8.2. Synthetic DNAs preferably are designed with convenient restriction sites engineered at the 5' and 3' ends of the gene to facilitate cloning into an appropriate vector.

As indicated, a method of generating variants is to start with one of the DNAs disclosed herein and then to conduct site-directed mutagenesis. See Ausubel *et al.*, *supra*, chapter 8, Supplement 37 (1997). In a typical method, a target DNA is cloned into a single-stranded DNA bacteriophage vehicle. Single-stranded DNA is isolated and hybridized with an oligonucleotide containing the desired nucleotide alteration(s). The complementary strand is synthesized and the double stranded phage is introduced into a host. Some of the resulting progeny will contain the desired mutant, which can be confirmed using DNA sequencing. In addition, various methods are available that increase the probability that the progeny phage will be the desired mutant. These methods are well

known to those in the field and kits are commercially available for generating such mutants.

Recombinant DNA constructs and expression

The present invention further provides for the use of recombinant DNA constructs comprising one or more of the nucleotide sequences of the present invention. The recombinant constructs are used in connection with a vector, such as a plasmid or viral vector, into which a DNA molecule encoding an antibody for use in the invention is inserted.

The encoded gene may be produced by techniques described in Sambrook *et al.*, 1989, and Ausubel *et al.*, 1989. Alternatively, the DNA sequences may be chemically synthesized using, for example, synthesizers. See, for example, the techniques described in OLIGONUCLEOTIDE SYNTHESIS (1984, Gait, ed., IRL Press, Oxford), which is incorporated by reference herein in its entirety. Recombinant constructs of the invention are comprised with expression vectors that are capable of expressing the RNA and/or protein products of the encoded DNA(s). The vector may further comprise regulatory sequences, including a promoter operably linked to the open reading frame (ORF). The vector may further comprise a selectable marker sequence. Specific initiation and bacterial secretory signals also may be required for efficient translation of inserted target gene coding sequences.

The present invention further provides for uses of host cells containing at least one of the DNAs disclosed herein. The host cell can be virtually any cell for which expression vectors are available. It may be, for example, a higher eukaryotic host cell, such as a mammalian cell, a lower eukaryotic host cell, such as a yeast cell, but preferably is a prokaryotic cell, such as a bacterial cell. Introduction of the recombinant construct into the host cell can be effected by calcium phosphate transfection, DEAE, dextran mediated transfection, electroporation or phage infection.

Useful expression vectors for bacterial use are constructed by inserting a structural DNA sequence encoding a desired protein together with suitable translation initiation and termination signals in operable reading phase with a functional promoter. The vector will
5 comprise one or more phenotypic selectable markers and an origin of replication to ensure maintenance of the vector and, if desirable, to provide amplification within the host. Suitable prokaryotic hosts for transformation include *E. coli*, *Bacillus subtilis*, *Salmonella typhimurium* and various species within the genera *Pseudomonas*, *Streptomyces*, and *Staphylococcus*.

10 Bacterial vectors may be, for example, bacteriophage-, plasmid- or phagemid-based. These vectors can contain a selectable marker and bacterial origin of replication derived from commercially available plasmids typically containing elements of the well known cloning vector pBR322 (ATCC 37017). Following transformation of a suitable host strain and growth of the host strain to an appropriate cell density, the selected promoter is de-
15 repressed/induced by appropriate means (*e.g.*, temperature shift or chemical induction) and cells are cultured for an additional period. Cells are typically harvested by centrifugation, disrupted by physical or chemical means, and the resulting crude extract retained for further purification.

In bacterial systems, a number of expression vectors may be advantageously selected
20 depending upon the use intended for the protein being expressed. For example, when a large quantity of such a protein is to be produced, for the generation of antibodies or to screen peptide libraries, for example, vectors which direct the expression of high levels of fusion protein products that are readily purified may be desirable.

Therapeutic Methods

25 Therapeutic methods involve administering to a subject in need of treatment a therapeutically effective amount of an antibody contemplated by the invention. A

"therapeutically effective" amount hereby is defined as the amount of an antibody that is of sufficient quantity to deplete CD38-positive cells in a treated area of a subject—either as a single dose or according to a multiple dose regimen, alone or in combination with other agents, which leads to the alleviation of an adverse condition, yet which amount is toxicologically tolerable. The subject may be a human or non-human animal (*e.g.*, rabbit, rat, mouse, monkey or other lower-order primate).

An antibody for use in the invention might be co-administered with known medicaments, and in some instances the antibody might itself be modified. For example, an antibody could be conjugated to an immunotoxin or radioisotope to potentially further increase efficacy.

The antibodies can be used as a therapeutic or a diagnostic tool in a variety of situations where CD38 is undesirably expressed or found. For example, in an *in vivo* study treating human myeloma xenografts in mice, the anti-tumor efficacy of intraperitoneally applied antibodies (HuCAL® anti-CD38) to the vehicle treatment (PBS) was compared. The human antibody hMOR03080 (isotype IgG1) was tested in different amounts and treatment schedules and it is assumed that the human antibodies MOR03077 and MOR03079 would lead to similar results than the tested antibody MOR03080.

Disorders and conditions particularly suitable for treatment with an antibody are multiple myeloma (MM) and other haematological diseases, such as chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML), acute myelogenous leukemia (AML), and acute lymphocytic leukemia (ALL). An antibody also might be used to treat inflammatory disease such as rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE).

To treat any of the foregoing disorders, pharmaceutical compositions for use in accordance with the present invention may be formulated in a conventional manner using one or more physiologically acceptable carriers or excipients. An antibody for use in the

invention can be administered by any suitable means, which can vary, depending on the type of disorder being treated. Possible administration routes include parenteral (*e.g.*, intramuscular, intravenous, intraarterial, intraperitoneal, or subcutaneous), intrapulmonary and intranasal, and, if desired for local immunosuppressive treatment, intralesional administration. In addition, an antibody for use in the invention might be administered by pulse infusion, with, *e.g.*, declining doses of the antibody. Preferably, the dosing is given by injections, most preferably intravenous or subcutaneous injections, depending in part on whether the administration is brief or chronic. The amount to be administered will depend on a variety of factors such as the clinical symptoms, weight of the individual, whether other drugs are administered. The skilled artisan will recognize that the route of administration will vary depending on the disorder or condition to be treated.

Determining a therapeutically effective amount of the novel polypeptide, according to this invention, largely will depend on particular patient characteristics, route of administration, and the nature of the disorder being treated. General guidance can be found, for example, in the publications of the International Conference on Harmonisation and in REMINGTON'S PHARMACEUTICAL SCIENCES, chapters 27 and 28, pp. 484-528 (18th ed., Alfonso R. Gennaro, Ed., Easton, Pa.: Mack Pub. Co., 1990). More specifically, determining a therapeutically effective amount will depend on such factors as toxicity and efficacy of the medicament. Toxicity may be determined using methods well known in the art and found in the foregoing references. Efficacy may be determined utilizing the same guidance in conjunction with the methods described below in the Examples.

Diagnostic Methods

CD38 is highly expressed on hematological cells in certain malignancies; thus, an anti-CD38 antibody for use in the invention may be employed in order to image or visualize a site of possible accumulation of malignant cells in a patient. In this regard, an antibody can be detectably labeled, through the use of radioisotopes, affinity labels (such

as biotin, avidin, etc.) fluorescent labels, paramagnetic atoms, etc. Procedures for accomplishing such labeling are well known to the art. Clinical application of antibodies in diagnostic imaging are reviewed by Grossman, H. B., Urol. Clin. North Amer. 13:465-474 (1986)), Unger, E. C. et al., Invest. Radiol. 20:693-700 (1985)), and Khaw, B. A. et al., Science 209:295-297 (1980)).

The detection of foci of such detectably labeled antibodies might be indicative of a site of tumor development, for example. In one embodiment, this examination is done by removing samples of tissue or blood and incubating such samples in the presence of the detectably labeled antibodies. In a preferred embodiment, this technique is done in a non-invasive manner through the use of magnetic imaging, fluorography, etc. Such a diagnostic test may be employed in monitoring the success of treatment of diseases, where presence or absence of CD38-positive cells is a relevant indicator. The invention also contemplates the use of an anti-CD38 antibody, as described herein for diagnostics in an ex vivo setting.

Therapeutic And Diagnostic Compositions

The antibodies for use in the present invention can be formulated according to known methods to prepare pharmaceutically useful compositions, wherein an antibody for use in the invention (including any functional fragment thereof) is combined in a mixture with a pharmaceutically acceptable carrier vehicle. Suitable vehicles and their formulation are described, for example, in REMINGTON'S PHARMACEUTICAL SCIENCES (18th ed., Alfonso R. Gennaro, Ed., Easton, Pa.: Mack Pub. Co., 1990). In order to form a pharmaceutically acceptable composition suitable for effective administration, such compositions will contain an effective amount of one or more of the antibodies for use in the present invention, together with a suitable amount of carrier vehicle.

Preparations may be suitably formulated to give controlled-release of the active compound. Controlled-release preparations may be achieved through the use of polymers to complex or absorb anti-CD38 antibody. The controlled delivery may be exercised by

selecting appropriate macromolecules (for example polyesters, polyamino acids, polyvinyl, pyrrolidone, ethylenevinyl-acetate, methylcellulose, carboxymethylcellulose, or protamine, sulfate) and the concentration of macromolecules as well as the methods of incorporation in order to control release. Another possible method to control the duration of action by controlled release preparations is to incorporate anti-CD38 antibody into particles of a polymeric material such as polyesters, polyamino acids, hydrogels, poly(lactic acid) or ethylene vinylacetate copolymers. Alternatively, instead of incorporating these agents into polymeric particles, it is possible to entrap these materials in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydroxymethylcellulose or gelatine-microcapsules and poly(methylmethacrylate) microcapsules, respectively, or in colloidal drug delivery systems, for example, liposomes, albumin microspheres, microemulsions, nanoparticles, and nanocapsules or in macroemulsions. Such techniques are disclosed in Remington's Pharmaceutical Sciences (1980).

The compounds may be formulated for parenteral administration by injection, *e.g.*, by bolus injection or continuous infusion. Formulations for injection may be presented in unit dosage form, *e.g.*, in ampules, or in multi-dose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents. Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, *e.g.*, sterile pyrogen-free water, before use.

The compositions may, if desired, be presented in a pack or dispenser device, which may contain one or more unit dosage forms containing the active ingredient. The pack may for example comprise metal or plastic foil, such as a blister pack. The pack or dispenser device may be accompanied by instructions for administration.

The invention further is understood by reference to the following working examples, which are intended to illustrate and, hence, not limit the invention.

EXAMPLES

Cell-lines

The following cell-lines were obtained from the European Collection of Cell Cultures (ECACC), the German Collection of Microorganisms (DSMZ) or the American Type Culture collection (ATCC): hybridoma cell line producing the CD38 mouse IgG1 monoclonal antibody OKT10 (ECACC, #87021903), Jurkat cells (DSMZ, ACC282), LP-1 (DSMZ, ACC41), RPMI8226 (ATCC, CCL-155), HEK293 (ATCC, CRL-1573), CHO-K1 (ATCC, CRL-61) and Raji (ATCC, CCL-86)

Cells and culture-conditions

All cells were cultured under standardized conditions at 37°C and 5% CO₂ in a humidified incubator. The cell-lines LP-1, RPMI8226, Jurkat and Raji were cultured in RPMI1640 (Pan biotech GmbH, #P04-16500) supplemented with 10 % FCS (PAN biotech GmbH, #P30-3302), 50 U/ml penicillin, 50 µg/ml streptomycin (Gibco, #15140-122) and 2 mM glutamine (Gibco, #25030-024) and, in case of Jurkat- and Raji-cells, additionally 10 mM Hepes (Pan biotech GmbH, #P05-01100) and 1 mM sodium pyruvate (Pan biotech GmbH, # P04-43100) had to be added.

CHO-K1 and HEK293 were grown in DMEM (Gibco, #10938-025) supplemented with 2 mM glutamine and 10% FCS. Stable CD38 CHO-K1 transfectants were maintained in the presence of G418 (PAA GmbH, P11-012) whereas for HEK293 the addition of 1mM sodium-pyruvate was essential. After transient transfection of HEK293 the 10% FCS was replaced by Ultra low IgG FCS (Invitrogen, #16250-078). The cell-line OKT10 was cultured in IDMEM (Gibco, #31980-022), supplemented with 2 mM glutamine and 20 % FCS.

Preparation of single cell suspensions from peripheral blood

All blood samples were taken after informed consent. Peripheral blood mononuclear cells (PBMC) were isolated by Histopaque®-1077 (Sigma) according to the manufacturer's instructions from healthy donors. Red blood cells were depleted from these cell suspensions by incubation in ACK Lysis Buffer (0.15 M NH₄Cl, 10 mM KHCO₃, 0.1 M EDTA) for 5 min at RT or a commercial derivative (Bioscience, #00-4333). Cells were washed twice with PBS and then further processed for flow cytometry or ADCC (see below).

Flow cytometry ("FACS")

All stainings were performed in round bottom 96-well culture plates (Nalge Nunc) with 2×10^5 cells per well. Cells were incubated with Fab or IgG antibodies at the indicated concentrations in 50 μ l FACS buffer (PBS, 3% FCS, 0.02% NaN_3) for 40 min at 4°C. Cells were washed twice and then incubated with R-Phycoerythrin (PE) conjugated goat-anti-human or goat-anti-mouse IgG (H+L) F(ab')₂ (Jackson Immuno Research), diluted 1:200 in FACS buffer, for 30 min at 4°C. Cells were again washed, resuspended in 0.3 ml FACS buffer and then analyzed by flow cytometry in a FACSCalibur (Becton Dickinson, San Diego, CA).

For FACS based Scatchard analyses RPMI8226 cells were stained with at 12 different dilutions (1:2ⁿ) starting at 12.5 μ g/ml (IgG) final concentration. At least two independent measurements were used for each concentration and K_D values extrapolated from median fluorescence intensities according to Chamow et al. (1994).

Surface plasmon resonance

The kinetic constants k_{on} and k_{off} were determined with serial dilutions of the respective Fab binding to covalently immobilized CD38-Fc fusion protein using the BIAcore 3000 instrument (Biacore, Uppsala, Sweden). For covalent antigen immobilization standard EDC-NHS amine coupling chemistry was used. For direct coupling of CD38 Fc-fusion protein CM5 sensor chips (Biacore) were coated with ~600-700 RU in 10 mM acetate buffer, pH 4.5. For the reference flow cell a respective amount of HSA (human serum albumin) was used. Kinetic measurements were done in PBS (136 mM NaCl, 2.7 mM KCl, 10mM Na_2HPO_4 , 1.76 mM KH_2PO_4 pH 7.4) at a flow rate of 20 μ l/min using Fab concentration range from 1.5-500 nM. Injection time for each concentration was 1 min, followed by 2 min dissociation phase. For regeneration 5 μ l 10mM HCl was used. All sensograms were fitted locally using BIA evaluation software 3.1 (Biacore).

EXAMPLE 1: Antibody Generation from HuCAL Libraries

For the generation of therapeutic antibodies against CD38, selections with the MorphoSys HuCAL GOLD phage display library were carried out. HuCAL GOLD[®] is a Fab library based on the HuCAL[®] concept (Knappik et al., 2000; Krebs et al., 2001), in which all six

CDRs are diversified, and which employs the CysDisplay™ technology for linking Fab fragments to the phage surface (Löhning, 2001).

A. Phagemid rescue, phage amplification and purification

HuCAL GOLD® phagemid library was amplified in 2 x TY medium containing 34
5 µg/ml chloramphenicol and 1 % glucose (2 x TY-CG). After helper phage infection
(VCSM13) at an OD600 of 0.5 (30 min at 37°C without shaking; 30 min at 37°C shaking
at 250 rpm), cells were spun down (4120 g; 5 min; 4°C), resuspended in 2 x TY / 34 µg/ml
chloramphenicol / 50 µg/ml kanamycin and grown overnight at 22°C. Phages were PEG-
precipitated from the supernatant, resuspended in PBS / 20 % glycerol and stored at -80°C.
10 Phage amplification between two panning rounds was conducted as follows: mid-log phase
TG1 cells were infected with eluted phages and plated onto LB-agar supplemented with
1 % of glucose and 34 µg/ml of chloramphenicol (LB-CG). After overnight incubation at
30°C, colonies were scraped off, adjusted to an OD600 of 0.5 and helper phage added as
described above.

B. Pannings with HuCAL GOLD®

For the selections HuCAL GOLD® antibody-phages were divided into three pools corresponding to different VH master genes (pool 1: VH1/5λκ, pool 2: VH3 λκ, pool 3: VH2/4/6 λκ). These pools were individually subjected to 3 rounds of whole cell panning on CD38-expressing CHO-K1 cells followed by pH-elution and a post-adsorption step on CD38-negative CHO-K1-cells for depletion of irrelevant antibody-phages. Finally, the remaining antibody phages were used to infect E. coli TG1 cells. After centrifugation the bacterial pellet was resuspended in 2 x TY medium, plated on agar plates and incubated overnight at 30°C. The selected clones were then scraped from the plates, phages were rescued and amplified. The second and the third round of selections were performed as the initial one.

The Fab encoding inserts of the selected HuCAL GOLD® phages were subcloned into the expression vector pMORPH®x9_Fab_FS (Rauchenberger et al., 2003) to facilitate rapid expression of soluble Fab. The DNA of the selected clones was digested with XbaI and EcoRI thereby cutting out the Fab encoding insert (ompA-VLCL and phoA-Fd), and cloned into the XbaI / EcoRI cut vector pMORPH®x9_Fab_FS. Fab expressed in this vector carry two C-terminal tags (FLAG™ and Strep-tag® II) for detection and purification.

EXAMPLE 2: Biological assays

Antibody dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity was measured according to a published protocol based on flow-cytometry analysis (Naundorf et al., 2002) as follows:

ADCC:

For ADCC measurements, target cells (T) were adjusted to 2.0E+05 cells/ml and labeled with 100 ng/ml Calcein AM (Molecular Probes, C-3099) in RPMI1640 medium (Pan

biotech GmbH) for 2 minutes at room temperature. Residual calcein was removed by 3 washing steps in RPMI1640 medium. In parallel PBMC were prepared as source for (natural killer) effector cells (E), adjusted to 1.0E+07 and mixed with the labeled target cells to yield a final E:T-ratio of 50:1 or less, depending on the assay conditions. Cells were washed once and the cell-mix resuspended in 200 µl RPMI1640 medium containing the respective antibody at different dilutions. The plate was incubated for 4 hrs under standardized conditions at 37°C and 5% CO₂ in a humidified incubator. Prior to FACS analysis cells were labeled with propidium-iodide (PI) and analyzed by flow-cytometry (Becton-Dickinson). Between 50.000 and 150.000 events were counted for each assay.

The following equation gave rise to the killing activity [in %]:

$$\frac{ED^A}{EL^A + ED^A} \times 100$$

with ED^A = events dead cells (calcein + PI stained cells), and
 EL^A = events living cells (calcein stained cells)

CDC:

For CDC measurements, 5.0E+04 CD38 CHO-K1 transfectants were added to a microtiter well plate (Nunc) together with a 1:4 dilution of human serum (Sigma, #S-1764) and the respective antibody. All reagents and cells were diluted in RPMI1640 medium (Pan biotech GmbH) supplemented with 10% FCS. The reaction-mix was incubated for 2 hrs under standardized conditions at 37°C and 5% CO₂ in a humidified incubator. As negative controls served either heat-inactivated complement or CD38-transfectants without antibody. Cells were labeled with PI and subjected to FACS-analysis.

In total 5000 events were counted and the number of dead cells at different antibody concentrations used for the determination of EC50 values. The following equation gave rise to the killing activity [in %]:

$$\frac{ED^C}{EL^C + ED^C} \times 100$$

with ED^C = events dead cells (PI stained cells), and
 EL^C = events living cells (unstained)

Cytotoxicity values from a total of 12 different antibody-dilutions (1:2ⁿ) in
5 triplicates were used in ADCC and duplicates in CDC for each antibody in order obtain
EC-50 values with a standard analysis software (PRISM[®], Graph Pad Software).

EXAMPLE 3: Generation of stable CD38-transfectants and CD38 Fc-fusion proteins

In order to generate CD38 protein for panning and screening two different
10 expression systems had to be established. The first strategy included the generation of
CD38-Fc-fusion protein, which was purified from supernatants after transient transfection
of HEK293 cells. The second strategy involved the generation of a stable CHO-K1 –cell
line for high CD38 surface expression to be used for selection of antibody-phages via
whole cell panning.

15 As an initial step Jurkat cells (DSMZ ACC282) were used for the generation of
cDNA (Invitrogen) followed by amplification of the entire CD38-coding sequence using
primers complementary to the first 7 and the last 9 codons of CD38, respectively (primer
MTE001 & MTE002rev; Table 4). Sequence analysis of the CD38-insert confirmed the
published amino acid sequence by Jackson et al. (1990) except for position 49 which
20 revealed a glutamine instead of a tyrosine as described by Nata et al. (1997). For
introduction of restriction endonuclease sites and cloning into different derivatives of
expression vector pcDNA3.1 (Stratagene), the purified PCR-product served as a template
for the re-amplification of the entire gene (primers MTE006 & MTE007rev, Table 4) or a
part (primers MTE004 & MTE009rev, Table 4) of it. In the latter case a fragment encoding
25 for the extracellular domain (aa 45 to 300) was amplified and cloned in frame between a
human V κ leader sequence and a human Fc-gamma 1 sequence. This vector served as

expression vector for the generation of soluble CD38-Fc fusion-protein. Another pcDNA3.1-derivative without leader-sequence was used for insertion of the CD38 full-length gene. In this case a stop codon in front of the Fc-coding region and the missing leader-sequence gave rise to CD38-surface expression. HEK293 cells were transiently transfected with the Fc-fusion protein vector for generation of soluble CD38 Fc-fusion protein and, in case of the full-length derivative, CHO-K1-cells were transfected for the generation of a stable CD38-expressing cell line.

Table 4:

Primer #	Sequence (5' -> 3')
MTE001	ATG GCC AAC TGC GAG TTC AGC (SEQ ID NO: 25)
MTE002rev	TCA GAT CTC AGA TGT GCA AGA TGA ATC (SEQ ID NO: 26)
MTE004	TT GGT ACC AGG TGG CGC CAG CAG TG (SEQ ID NO: 27)
MTE006	TT GGT ACC ATG GCC AAC TGC GAG (SEQ ID NO: 28)
MTE007rev	CCG ATA TCA* GAT CTC AGA TGT GCA AGA TG (SEQ ID NO: 29)
MTE009rev	CCG ATA TC GAT CTC AGA TGT GCA AGA TG (SEQ ID NO: 30)

* leading to a stop codon (TGA) in the sense orientation.

EXAMPLE 4: Cloning, expression and purification of HuCAL[®] IgG1:

In order to express full length IgG, variable domain fragments of heavy (VH) and light chains (VL) were subcloned from Fab expression vectors into appropriate pMORPH[®]_hlg vectors (see Figures 8 to 10). Restriction endonuclease pairs BlnI/MfeI (insert-preparation) and BlnI/EcoRI (vector-preparation) were used for subcloning of the VH domain fragment into pMORPH[®]_hIgG1. Enzyme-pairs EcoRV/HpaI (lambda-insert) and EcoRV/BsiWI (kappa-insert) were used for subcloning of the VL domain fragment into the respective pMORPH[®]_hlgκ_1 or pMORPH[®]_h_Igλ_1 vectors. Resulting IgG

constructs were expressed in HEK293 cells (ATCC CRL-1573) by transient transfection using standard calcium phosphate –DNA coprecipitation technique.

IgGs were purified from cell culture supernatants by affinity chromatography via Protein A Sepharose column. Further down stream processing included a buffer exchange by gel filtration and sterile filtration of purified IgG. Quality control revealed a purity of >90 % by reducing SDS-PAGE and >90 % monomeric IgG as determined by analytical size exclusion chromatography. The endotoxin content of the material was determined by a kinetic LAL based assay (Cambrex European Endotoxin Testing Service, Belgium).

EXAMPLE 5: Generation and production of chimeric OKT10 (chOKT10; SEQ ID NOS: 23 and 24)

For the construction of chOKT10 the mouse VH and VL regions were amplified by PCR using cDNA prepared from the murine OKT10 hybridoma cell line (ECACC #87021903). A set of primers was used as published (Dattamajumdar et al., 1996; Zhou et al., 1994).

PCR products were used for Topo-cloning (Invitrogen; pCRII-vector) and single colonies subjected to sequence analysis (M13 reverse primer) which revealed two different kappa light chain sequences and one heavy chain sequence. According to sequence alignments (EMBL-nucleotide sequence database) and literature (Krebber et al, 1997) one of the kappa-sequence belongs to the intrinsic repertoire of the tumor cell fusion partner X63Ag8.653 and hence does not belong to OKT10 antibody. Therefore, only the new kappa sequence and the single VH-fragment was used for further cloning. Both fragments were reamplified for the addition of restriction endonuclease sites followed by cloning into the respective pMORPH® IgG1-expression vectors. The sequences for the heavy chain (SEQ ID NO: 23) and light chain (SEQ ID NO: 24) are given in Fig. 6. HEK293 cells were transfected transiently and the supernatant analyzed in FACS for the chimeric OKT10 antibody binding to the CD38 over-expressing Raji cell line (ATCC).

EXAMPLE 6: Epitope Mapping**1. Materials and Methods:****Antibodies:**

The following anti-CD38 IgGs were sent for epitope mappings:

MOR#	Lot #	Format	Conc. [mg/ml]/Vol.[μl]
MOR03077	2CHE106_030602	human IgG1	0.44/1500
MOR03079	2APO31	human IgG1	0.38/500
MOR03080	030116_4CUE16	human IgG1	2.28/200
MOR03100	030612_6SBA6	human IgG1	0.39/500
chim. OKT10*	030603_2CHE111	human IgG1	0.83/500

* chimeric OKT10 consisting of human Fc and mouse variable regions.

CD38-Sequence:

The amino acid (aa) sequence (position 44 – 300) is based on human CD38 taken from the published sequence under SWISS-PROT primary accession number P28907. At position 49 the aa Q (instead of T) has been used for the peptide-design.

PepSpot-Analysis:

The antigen peptides were synthesized on a cellulose membrane in a stepwise manner resulting in a defined arrangement (peptide array) and are covalently bound to the cellulose membrane. Binding assays were performed directly on the peptide array.

In general an antigen peptide array is incubated with blocking buffer for several hours to reduce non-specific binding of the antibodies. The incubation with the primary (antigen peptide-binding) antibody in blocking buffer occurs followed by the incubation with the peroxidase (POD)-labelled secondary antibody, which binds selectively the primary antibody. A short T (Tween)-TBS-buffer washing directly after the incubation of the antigen peptide array with the secondary antibody followed by the first chemiluminescence

experiment is made to get a first overview which antigen peptides do bind the primary antibody. Several buffer washing steps follow (T-TBS- and TBS-buffer) to reduce false positive binding (unspecific antibody binding to the cellulose membrane itself). After these washing steps the final chemiluminescence analysis is performed. The data were analysed with an imaging system showing the signal intensity (Boehringer Light units, BLU) as single measurements for each peptide. In order to evaluate non-specific binding of the secondary antibodies (anti-human IgG), these antibodies were incubated with the peptide array in the absence of primary antibodies as the first step. If the primary antibody does not show any binding to the peptides it can be directly labelled with POD, which increases the sensitivity of the system (as performed for MOR3077). In this case a conventional coupling chemistry *via* free amino-groups is performed.

The antigen was scanned with 13-mer peptides (11 amino acids overlap). This resulted in arrays of 123 peptides. Binding assays were performed directly on the array. The peptide-bound antibodies MOR03077, MOR03079, MOR03080, MOR03100 and chimeric OKT10 were detected using a peroxidase-labelled secondary antibody (peroxidase conjugate-goat anti-human IgG, gamma chain specific, affinity isolated antibody; Sigma-Aldrich, A6029). The mappings were performed with a chemiluminescence substrate in combination with an imaging system. Additionally, a direct POD-labelling of MOR03077 was performed in order to increase the sensitivity of the system.

2. Summary and Conclusions:

All five antibodies showed different profiles in the PepSpot analysis. A schematic summary is given in Fig. 7, which illustrates the different aa sequences of CD38 being recognized. The epitope for MOR03079 and chimeric OKT10 can clearly be considered as linear. The epitope for MOR03079 can be postulated within aa 192 – 206

(VSRRFAEAACDVVHV) of CD38 whereas for chimeric OKT10 a sequence between aa 284 and 298 (FLQCVKNPEDSSCTS) is recognized predominantly. The latter results confirm the published data for the parental murine OKT10 (Hoshino *et al.*, 1997), which postulate its epitope between aa 280-298. Yet, for a more precise epitope definition and determination of key amino acids (main antigen-antibody interaction sites) a shortening of peptides VSRRFAEAACDVVHV and FLQCVKNPEDSSCTS and an alanine-scan of both should be envisaged.

The epitopes for MOR03080 and MOR03100 can be clearly considered as discontinuous since several peptides covering different sites of the protein sites were recognized. Those peptides comprise aa 82-94 and aa 158-170 for MOR03080 and aa 82-94, 142-154, 158-170, 188-200 and 280-296 for MOR03100. However, some overlaps between both epitopes can be postulated since two different sites residing within aa positions 82-94 (CQSVWDAFKGAFI; peptide #20) and 158-170 (TWCGEFNTSKINY; peptide #58) are recognized by both antibodies.

The epitope for MOR03077 can be considered as clearly different from the latter two and can be described as multisegmented discontinuous epitope. The epitope includes aa 44-66, 110-122, 148-164, 186-200 and 202-224.

Example 6A:

As described above, MOR03077, 03080, and 03100 recognize discontinuous epitopes, whereas the epitope of MOR03079 and OKT10 can be described as linear. Interestingly MOR03080 and MOR03100 recognize strongly peptides covering aa 280-298, which are not included in the reaction pattern of the other antibodies. The sequence of this 13 aa (amino acid) peptide is conserved between human and macaque species' CD38 (table 9) (Ferrero *et al.*, 2004) and thus might determine the cross-reactivity of both antibodies with non-human primates' CD38. A weaker reaction of MOR03080 is shown

for a second peptide (aa 158-170, (table 10), which shows a 2 aa difference to cynomolgus.

Both epitopes are most heterogeneous when compared to the corresponding sequence from other species, including rat (8 or 6 aa differences), mouse (6 aa differences), rabbit (9 aa differences) and dog (7 aa differences), supporting the specific binding behaviour of said

5 antibodies in IHC with the human and non-human primate tissues that were tested.. Amino acids 280-298 show also a very high homology between human and cynomolgus CD38 (only 1 aa difference at position 297), which includes the epitopes for the cross-reactive OKT10 (aa 284-298) and MOR03100 (aa 280-296). On the other hand this sequence is highly heterogeneous when compared to non-primate species exhibiting differences

10 between 6 (rat, mouse, dog) and 9 (rabbit) aa (table 11). MOR03077 and MOR03079 specifically bind to some of the peptides tested, which exhibit between 1 and 3 aa differences to the macaque sequence and even more differences to other species, supporting , inter alia, the specific binding behaviour of said antibodies to human hCD38.

An example for epitope aa 192-206 of MOR03079 is shown in table 12.

15

EXAMPLE 7: IL-6-release/proliferation assay

1. Materials and Methods:

20 Proliferation- and a IL-6 release and also IFN- γ assays have been performed according to Ausiello et al. (2000) with the following modifications: PBMCs from different healthy donors (after obtaining informed consent) were purified by density gradient centrifugation using the Histopaque cell separation system according to the instructions of the supplier (Sigma) and cultured under standard conditions (5% CO₂, 37°C) in

25 RPMI1640 medium, supplemented with 10% FCS and glutamine ("complete

RPMI1640"). For both assays the following antibodies were used: HuCAL® anti-CD38 IgG1s Mabs MOR03077, MOR03079, and MOR03080, an agonistic murine IgG2a monoclonal antibody (IB4; Malavasi et al., 1984), an irrelevant HuCAL® IgG1 antibody, a matched isotype control (murine IgG2a: anti-trinitrophenol, hapten-specific antibody; cat.#: 555571, clone G155-178; Becton Dickinson; not shown) or a medium control. For the IL-6 release assay, 1.0×10^6 PBMCs in 0.5 ml complete RPMI1640 medium were incubated for 24 hrs in a 15 ml culture tube (Falcon) in the presence of 20 µg/ml antibodies. Cell culture supernatants were harvested and analysed for IL-6 release using the Quantikine kit according to the manufacturer's protocol (R&D systems). For the proliferation assay 2.0×10^5 PBMCs were incubated for 3 days in a 96-well flat bottom plate (Nunc) in the presence of 20 µg/ml antibodies. Each assay was carried out in duplicates. After 4 days BrdU was added to each well and cells incubated for an additional 24 hrs at 37°C prior to cell fixation and DNA denaturation according to the protocol of the supplier (Roche). Incorporation of BrdU was measured via an anti-BrdU peroxidase-coupled antibody in a chemiluminescence-based setting.

2. Summary and Conclusions:

Proliferation Assay:

In addition to its catalytic activities as a cyclic ADP-ribose cyclase and hydrolase, CD38 displays the ability to transduce signals of biological relevance (Hoshino et al., 1997; Ausiello et al., 2000). Those functions can be induced in vivo by *e.g.* receptor-ligand interactions or by cross-linking with anti-CD38 antibodies. Those signalling events lead *e.g.* to calcium mobilization, lymphocyte proliferation and release of cytokines. However, this signalling is not only dependent on the antigenic epitope but might also vary from donor to donor (Ausiello et al., 2000). In the view of

immunotherapy non-agonistic antibodies are preferable over agonistic antibodies.

Therefore, HuCAL® anti-CD38 antibodies (Mabs MOR03077; MOR03079, MOR03080) were further characterized in a proliferation assay and IL-6- (important MM growth-factor) and IFN γ release assay in comparison to the reference antibody chOKT10 and the agonistic anti-CD38 monoclonal antibody IB4.

As demonstrated in Fig. 11 the HuCAL anti-CD38 antibodies Mab#1, 2 and 3 as well as the reference antibody chOKT10 and corresponding negative controls showed no or only weak induction of proliferation and no IL-6/IFN- γ -release as compared to the agonistic antibody IB4.

EXAMPLE 8: Clonogenic assay

1. Materials and Methods:

PBMCs harbouring autologous CD34+/CD38+ precursor cells were isolated from healthy individuals (after obtaining informed consent) by density gradient centrifugation using the Histopaque cell separation system according to the instructions of the supplier (Sigma) and incubated with different HuCAL® IgG1 anti-CD38 antibodies (Mabs MOR03077, MOR03079, and MOR03080) and the positive control (PC) chOKT10 at 10 μ g/ml. Medium and an irrelevant HuCAL® IgG1 served as background control. Each ADCC-assay consisted of 4.0E+05 PBMCs which were incubated for 4 hrs at 37°C in RPMI1640 medium supplemented with 10% FCS. For the clonogenic assay 2.50 ml “complete” methylcellulose (CellSystems) was inoculated with 2.5 E+05 cells from the ADCC-assay and incubated for colony-development for at least 14 days in a controlled environment (37°C; 5% CO₂). Colonies were analyzed by two independent operators and grouped into BFU-E +

CFU-GEMM (erythroid burst forming units and granulocyte/ erythroid / macrophage / megakaryocyte stem cells) and CFU-GM (granulocyte / macrophage stem cells).

2. Summary and Conclusions:

5 Since CD38-expression is not only found on immune cells within the myeloid (e.g. monocytes, granulocytes) and lymphoid lineage (e.g. activated B and T-cells; plasma cells) but also on the respective precursor cells (CD34+/CD38+), it is important that those cells are not affected by antibody-mediated killing. Therefore, a clonogenic assay was applied in order to analyse those effects on CD34+/CD38+ progenitors.

10 PBMCs from healthy donors were incubated with HuCAL® anti-CD38 antibodies (Mab#1, Mab#2 and Mab#3) or several controls (irrelevant HuCAL® antibody, medium and reference antibody chOKT10 as positive control) according to a standard ADCC-protocol followed by further incubation in conditioned methylcellulose for colony-development. As shown in Fig. 13 no significant reduction of colony-forming
15 units are shown for all HuCAL® anti-CD38 antibodies as compared to an irrelevant antibody or the reference antibody.

EXAMPLE 9: ADCC Assays with different cell-lines and primary multiple myeloma cells

20 1. Materials and Methods:

Isolation and ADCC of MM-patient samples: Bone marrow aspirates were obtained from multiple myeloma patients (after obtaining informed consent). Malignant cells were purified via a standard protocol using anti-CD138 magnetic beads (Milteny Biotec) after density gradient centrifugation (Sigma). An ADCC-assay was performed
25 as described before.

2. Summary and Conclusions:

Several cell-lines derived from different malignancies were used in ADCC in order to show the cytotoxic effect of the HuCAL® anti-CD38 antibodies on a broader spectrum of cell-lines including different origins and CD38 expression-levels. As shown in Figure 14, all cells were killed in ADCC at constant antibody concentrations (5 µg/ml) and E:T ratios at 30:1. Cytotoxicity via ADCC was also shown for several multiple myeloma samples from patients. All HuCAL® anti-CD38 antibodies were able to perform a dose-dependent killing of MM-cells and the EC₅₀-values varied between 0.006 and 0.249 nM (Figure 15).

EXAMPLE 9A: Cytotoxic activity: Complement-dependent cytotoxicity (CDC) and Antibody-dependent cellular cytotoxicity (ADCC)

Complement-dependent cytotoxicity (CDC)

The representative anti-hCD38 antibodies of the invention were tested in CDC on hCD38-transfectants. The resulting EC₅₀ values ranged from 0.41 to 13.61 nM (table 2 and table 13). Except for MOR03100 all HuCAL® anti-hCD38 showed at least a 3-fold better EC₅₀ value compared to the reference antibody chOKT10. In all cases maximum specific cytotoxicity varied between 75-90% . An example is shown for chOKT10 and MOR03079 in Fig. 19. Among the different tumor cell lines (Raji, RPMI8226 and LP-1) only LP-1 was susceptible to CDC-mediated lysis although to a lower extent (20-40% of specific killing). In this case EC₅₀ values of 5.6 and 0.55 nM could be determined for MOR03077 and MOR03079, respectively.

Antibody-dependent cellular cytotoxicity (ADCC)

All four representative antibodies of the invention were able to kill MM cell lines RPMI8226 and LP-1 in a dose-dependent manner using effector cells from healthy volunteers at an E:T-ratio of 30:1. EC₅₀ values range from 40 pM to 1.0 nM as shown in table 2 and table 13. A number of other cell lines from different indications were included in this proof of *in vitro* efficacy and maximal specific killing was determined using anti-hCD38 antibodies MOR03077, MOR03079 and MOR03080. The maximal specific killing rates of up to 73% (Fig. 14) fall within the published range of ADCC results despite the fact, that different assay sets (e.g. read out) and targets have been used (Ellis *et al.*, 1995; Flavell *et al.*, 2001, Naundorf *et al.*, 2003; Shinkawa *et al.*, 2003; Hayashi *et al.*, 2003; Golay *et al.*, 2000; Reff *et al.*, 1994; Santi *et al.*, 2002; Kono *et al.*, 2002).

Among the different cell lines used for ADCC hCD38-expression was highly variable (as determined by mean-fluorescence intensities) but no correlation could be made between the expression level and the susceptibility to ADCC (Fig. 14). However, different expression levels of hCD38 within the same cell line corresponded well with the specific killing-rates when hCD38-expression was induced or enhanced by the addition of retinoic acid (Mehta *et al.*, 2004; data not shown). In a second proof of *in vitro* efficacy ADCC-mediated killing could be demonstrated for all primary MM samples (figure 20) derived from the bone marrow of patients after density gradient purification and enrichment by anti-CD138 beads. Additionally, a single patient sample of plasma cell leukemia which included ~90% of tumor cells after density gradient centrifugation was successfully killed. As shown in Fig. 14 strong variations in EC₅₀ values for the individual anti-hCD38 antibodies were observed which might be due to the heterogeneity of the primary MM material in combination with different PBMC donors. However, EC₅₀ values were in the same range as observed for established MM cell lines. In conclusion, all cell lines and MM samples that express hCD38 could be killed in ADCC to various extent by the anti-hCD38

antibodies and only minor differences among the HuCAL[®] hCD38 antibodies were found except for MOR03100 which was less efficient as judged from its EC₅₀ values. The reference antibody chOKT10 exhibited the lowest efficacy in ADCC among all tested anti-hCD38 antibodies, which is in good agreement with the affinity determinations.

5

EXAMPLE 10: Cross-reactivity analysis by FACS and immunohisto-chemistry (IHC)

Binding of the HuCAL antibodies to target cells is shown using FACS and IHC analysis (table 5, fig. 17). The binding to non-target cells, such as the binding of MOR03079 to erythrocytes, could be desirable for specific therapeutic uses of the compound. One such use would be to alter the half-life of the compound through the specific interaction of the antibody to the erythrocytes. However, if a specific interaction between the therapeutic antibody and a non-target cell is undesirable, antibodies that bind target cells significantly better compared to the non-target cells could be identified and utilized. The following example characterises the recognition of the HuCAL antibodies for target and non-target cells. In addition, cross-reactivity to these target and non-target cells of other species is characterised to identify a proper animal species for toxicity and safety studies.

1. Materials and Methods:

FACS analysis of lymphocytes: EDTA-treated blood samples were obtained from healthy humans (after obtaining informed consent), from non human primates (Rhesus, Cynomolgus and Marmoset), dogs, minipigs, rabbits, rat and mouse were subjected to density gradient centrifugation using the Histopaque cell separation system according to the instructions of the supplier (Sigma). For FACS-analysis, cells from the interphase

(PBMC-fraction) and pellet (Erythrocyte-fraction) were incubated with anti-CD38 HuCAL® antibodies in different formats (fully human IgG1: MOR03077, MOR03079 and MOR03080; chimeric IgG2a [Fc gamma 2a fused to the human variable region]: MOR03077, MOR03079 and MOR03080), the reference antibody chOKT10 (ch: 5 chimeric; human Fc gamma 1 fused to mouse variable region) and several commercially available CD38-specific murine monoclonal antibodies (OKT10 , IB4, AT1, AT13/5, HB7 and T16) as well as a matched isotype negative control). After several washes in FACS-buffer (PBS + 3%FCS), bound primary antibodies were detected with phycoerythrin (PE)-labelled anti-mouse or anti-human conjugates (Jackson Research). FACS analysis was 10 performed on the gated lymphocyte population.

FACS analysis of spleen and lymph-node cells: Animals were sacrificed and spleen and lymph-nodes were removed. Spleen and lymph-nodes were cut into small pieces (1 mm³) and passed through a steel mesh into a petri-dish containing cell-culture medium (RPMI1640, 10% FCS). In order to remove fat, cell debris and aggregates, the cells were 15 further passed through a cotton wool column. After a microscopic check to confirm single cell-suspension, cells were washed several times and subjected to density gradient centrifugation for removal of dead cells and contaminating erythrocytes. Cells from the interphase were subjected to FACS analysis as described above.

20 2. Summary and Conclusions:

All HuCAL® anti-CD38 Mabs were able to detect human CD38 on lymphocytes in FACS (Fig. 17). Positive staining of erythrocytes could be demonstrated for MOR03079 and to a weaker extent by MOR03080. MOR03077 did not react with human erythrocytes. MOR03080 was cross-reactive on cynomolgus and rhesus lymphocytes and erythrocytes, 25 whereas MOR03077 reacted with minipig and rabbit lymphocytes but not on the

corresponding red blood cells. In order to confirm cross-reactivity of MOR03077 on minipig and rabbit, cells from spleen and lymph-nodes were subjected to FACS-analysis. Both additional cell-types confirmed previous results (table. 5). The cross-reactivity on rhesus and cyno as well those on minipig and rabbit could be also confirmed by mouse monoclonal antibodies OKT10 and IB4 (Fig. 17), respectively.

Table 5:

Species \ Antibody ^h	MAb#1	MAB#2	MAB#3	OKT10	IB4
Human ^a	++ ^f	++	++	++	++ ^d
Cynomolgus Monkey ^a	-	-	++	++	- ^d
Rhesus Monkey ^a	-	-	++	++	n.d.
Baboon Monkey ^e	-	-	++	n.d.	n.d.
Marmoset Monkey ^a	-	-	-	-	- ^d
Dog ^d	-	-	-	-	-
Minipig ^g	+	-	-	-	+
Rabbit ^g	+/-	-	-	-	+
Mouse ^c	-	-	-	-	n.d.
Rat ^b	-	-	-	-	-

^a: FACS: lymphocytes; IHC: spleen, lymph-nodes

^b: FACS: lymphocytes, spleen; IHC: spleen

^c: IHC: lymph nodes

^d: FACS: lymphocytes

^e: IHC: spleen, lymph-nodes

^f: IHC: negative on lymph-nodes

^g: FACS: lymphocytes, spleen, lymph-nodes

^h: Formats: MAb#1-3: chimeric: human variable domaine/murine Fc 2a

OKT10: murine MAb IgG1

IB4: murine MAb IgG2a

++: strong positive staining

+: positive staining

+/-: weak positive staining

n.d.: not determined

IHC: Immuno-histochemistry
(use of cryo material)

MAb#1 = MOR03077

MAb#2 = MOR03079

MAb#3 = MOR03080

Example 10A: Analysis of hCD38 expression on human normal tissues

All representative HuCAL[®] anti-hCD38 antibodies of the invention reacted with
5 tissue from the human lymphoid system (table 14) including thymus, tonsils, lymph nodes
and spleen except for MOR03077 which showed no positive reaction in any of the
examined human lymph node sections (n=2 donors). This may be caused by an altered
accessibility of the respective hCD38 epitope in lymph nodes or weak antibody antigen
interaction on this tissue specimen. In blood hCD38 expression can be detected on
10 lymphocytes by all antibodies whereas in one case (MOR03079) hCD38-expression was
also detected on human erythrocytes (n > 3 donors) – although to a very low extent. The
latter result may be due to the high affinity of said antibody since another anti-hCD38
antibody (MAb IB4) with comparable affinities exhibited the same FACS-shift on
erythrocytes (not shown). Among the different tissues prostate was hCD38-positive for all
15 antibodies, which stained the epithelium of prostate glandules and connective tissue. In
muscle all representative anti-hCD38 antibodies were tested negative. The IHC results for
cerebellum and pancreas were most heterogenous among the panel of anti-hCD38
antibodies, suggesting an altered accessibility, e.g. by conformational changes or masking,
of the hCD38 molecule. Neurons in the cerebellum showed a strong hCD38 expression
20 with the reference antibody murine OKT10 but only a very weak staining with the
HuCAL[®] anti-hCD38 antibodies. In pancreas only MOR03100 showed a strong
cytoplasmic hCD38 expression of the glandular cells within the exocrine part of the
pancreas. Surprisingly, the islets of Langerhans (Antonelli *et al.*, 2001; Maloney *et al.*,
2002; Marchetti, 2002), which are reported to express hCD38, showed no reaction in the
25 IHC studies. In summary, the IHC and FACS data of the HuCAL[®] MOR03077, 03079 and
03080 resemble those shown by an RNA dot blot analysis using human multiple tissue
array (Mehta *et al.*, 2004). Those data revealed that hCD38-expression is highest in

thymus and moderate to low in spleen, lymph nodes and prostate. In all other human tissues, hCD38 expression was either absent or barely detectable.

5

EXAMPLE 11: Treatment of human myeloma xenografts in mice (using the RPMI8226 cell line) with MOR03080

10 **1. Establishment of subcutaneous mouse model:**

A subcutaneous mouse model for the human myeloma-derived tumor cell line RPMI8226 in female C.B-17-SCID mice was established as follows by Aurigon Life Science GmbH (Tutzing, Germany): on day -1, 0, and 1, anti-asialo GM1 polyclonal antibodies (ASGM) (WAKO-Chemicals), which deplete the xenoreactive NK-cells in the
15 SCID mice were applied intravenously in order to deactivate any residual specific immune reactivity in C.B-17-SCID mice. On day 0, either 5×10^6 or 1×10^7 RPMI8226 tumor cells in 50 μ l PBS were inoculated subcutaneously into the right flank of mice either treated with ASGM (as described above) or untreated (each group consisting of five mice). Tumor development was similar in all 4 inoculated groups with no significant difference being
20 found for treatment with or without anti-asialo GM1 antibodies or by inoculation of different cell numbers. Tumors appear to be slowly growing with the tendency of stagnation or oscillation in size for some days. Two tumors oscillated in size during the whole period of investigation, and one tumor even regressed and disappeared totally from a peak volume of 321 mm³. A treatment study with this tumor model should include a high
25 number of tumor-inoculated animals per group.

2. Treatment with MOR03080:

2.1 Study objective

This study was performed by Aurigon Life Science GmbH (Tutzing, Germany) to compare the anti-tumor efficacy of intraperitoneally applied antibodies (HuCAL® anti-CD38) as compared to the vehicle treatment (PBS). The human antibody hMOR03080 (isotype IgG1) was tested in different amounts and treatment schedules. In addition the chimeric antibody chMOR03080 (isotype IgG2a: a chimeric antibody comprising the variable regions of MOR03080 and murine constant regions constructed in a similar way as described in Example 5 for chimeric OKT10 (murine VH/VL and human constant regions)) was tested. The RPMI8226 cancer cell line had been chosen as a model and was inoculated subcutaneously in female SCID mice as described above. The endpoints in the study were body weight (b.w.), tumor volume and clinical signs.

2.2 Antibodies and vehicle

The antibodies were provided ready to use to Aurigon at concentrations of 2.13 mg/ml (MOR03080 hIgG1) and 1.73 mg/ml (MOR03080 chIgG2a, and stored at -80°C until application. The antibodies were thawed and diluted with PBS to the respective end concentration. The vehicle (PBS) was provided ready to use to Aurigon and stored at 4°C until application.

2.3 Animal specification

Species: mouse

Strain: Fox chase C.B-17-scid (C.B-Igh-1b/lcrTac)

Number and sex: 75 females

Supplier: Taconic M&B, Bomholtvej 10, DK-8680 Ry

Health status: SPF

Weight ordered: appr. 18 g

Acclimatization: 9 days

5

2.4 Tumor cell line

The tumor cells (RPMI8226 cell line) were grown and transported to Aurigon Life Science GmbH, where the cells were splitted and grown for another cycle. Aurigon
10 prepared the cells for injection on the day of inoculation. The culture medium used for cell propagation was RPMI 1640 supplemented with 5% FCS, 2 mM L-Glutamin and PenStrep. The cells showed no unexpected growth rate or behaviour.

For inoculation, tumor cells were suspended in PBS and adjusted to a final concentration of 1×10^7 cells / 50 μ l in PBS. The tumor cell suspension was mixed
15 thoroughly before being injected.

2.5 Experimental procedure

On day 0, 1×10^7 RPMI8226 tumor cells were inoculated subcutaneously into the right dorsal flank of 75 SCID mice. A first group was built with 15 randomly chosen animals
20 (group 5) directly after inoculation. This group was treated with 1 mg/kg b.w. hIgG1-MOR03080 every second day between day 14 and 36. From all other 60 animals 4 groups were built with ten animals in each group on day 31 (tumor volume of about 92 mm³). Groups 1-4 were built with comparable means tumor sizes and standard deviations. An additional group of 5 animals (group 6) was chosen showing relatively small tumor
25 volumes (tumor volume of about 50 mm³) for comparison with pre-treated group 5 (all but

three mice showing tumor volumes of less than 10 mm³, one with about 22 mm³, one with about 44 mm³ and one with about 119 mm³). Groups 1 to 4 were treated every second day from day 32 to day 68 with either PBS (Vehicle; group 1), 1 mg/kg b.w. hIgG1-MOR03080 (group 2) or 5 mg/kg b.w. hIgG1-MOR03080 (group 3), or with 5 mg/kg b.w. chIgG2a-MOR03080 (group 4). Group 6 did not receive any treatment (see Table 6). Tumor volumes, body weight and clinical signs were measured two times a week until end of study.

Table 6:

Group	No. of animals	Type of application	Substance	Schedule	Treatment dose [mg/kg]	Appl. volume [μl/kg]
1	10	i.p.	vehicle (PBS)	every second day between day 32 and day 68	--	10
2	10	i.p.	MOR03080 human IgG1	every second day between day 32 and day 68	1	10
3	10	i.p.	MOR03080 human IgG1	every second day between day 32 and day 68	5	10
4	10	i.p.	MOR03080 chimeric IgG2a	every second day between day 32 and day 68	5	10
5	15	i.p.	MOR03080 human IgG1	every second day between day 14 and day 36	1	10
6	5	--	--	--	--	--

2.6 Results

Clinical observations and mortality

No specific tumor or substance related clinical findings or mortality were observed. In group 3 (hIgG1 5 mg/kg) four animals died during blood sampling (one on day 3, one on day 34; two on day 52). In group 4 (mulgG2a 1 mg/kg) a single animal died during blood sampling (day 34). All other animals, that died during the study have been euthanized because of the tumor size.

Body weight development

No drug related interference with weight development was observed in comparison to group 1 (vehicle). Body weight was markedly influenced by blood sampling in groups 3 (hIgG1 5 mg/kg) and 4 (mIgG2a 5 mg/kg). Despite such interruptions the mean weight gain of all groups was continuous.

5

Tumor development (see Figure 16)

In group 1 (vehicle) tumor growth was found in the expected rate with a slow progression. As this cell line has a pronounced standard deviation values for the largest and smallest tumor have been excluded from further statistical analysis. The tumor growth of animals in group 1 was comparable to the tumor growth in group 6 (untreated), although this group started with a lower mean tumor volume on day 31. Treatment might therefore have a slight influence on the tumor growth rate. In group 1, two mice had to be euthanized before day 83 because of the tumor size, and a further one before day 87, so that the mean value of tumor volume is no longer representative after day 80. In group 6, one mouse had to be euthanized before day 80 because of the tumor size, two mice before day 83, and a further one before day 87, so that the mean value of tumor volume is no longer representative after day 76.

In group 2, treated with 1 mg/kg b.w. of hIgG1, one animal has been excluded from further analysis, because the tumor grew into the muscular tissue and this usually enhances the speed of tumor growth. Compared with the control group 1 (vehicle) the mean tumor size started to differ significantly starting with day 45 until the end of the study. No enhanced tumor growth was observed after end of treatment (day 68).

25

Animals of group 3 (5 mg/kg b.w. hIgG1) revealed a marked decrease in tumor growth in comparison to group 1 (vehicle), getting statistically significant with day 38 until day 83. The mean tumor volume started to strongly regrow about two weeks after the end of treatment. One out of ten tumors disappeared at day 45 and did not regrow up to 19 days after end of treatment.

30

The best performance of all treatment groups starting with 92 mm³ tumor volume was found in group 4 (5 mg/kg b.w. mIgG2a), where the mean tumor volume showed clear regression and tumors even disappeared in 4 animals until the end of the observation

period. The difference to the mean tumor volume of group 1 (vehicle) was highly significant beginning from day 38 until the end of study.

The early treatment with 1 mg/kg b.w. hIgG1 between days 14 and 36 (group 5) revealed an early as well as long lasting effect on tumor development. One animal has been excluded from further analysis as the tumor grew into muscular tissue. On day 31, only five animals had a measurable tumor at the site of inoculation, in comparison to the rest of the inoculated animals, where only 2 out of 60 did not respond to tumor inoculation. The tumor progression was delayed of about 31 days (comparison of day 52 of control group 1 with day 83 of group 5). About 50% of the animals did not show tumors at the site of inoculation at the end of the study.

2.7 Conclusion

No specific tumor or substance related clinical findings or mortality were observed in comparison with group1 (control).

No drug related interference with weight development was observed.

Tumor growth of RPMI8226 tumor cells after treatment was reduced in the order of efficiency: hIgG1 1 mg/kg, 14-36 days every second day (group 5) > muIgG2a 5 mg/kg 32-68 days every second day (group 4) > hIgG1 5 mg/kg 32-68 days every second day (group 3) > hIgG1 1mg/kg 32-68 days every second day (group 2). In groups 2 to 4, mean tumor volumes were again increased after end of treatment to varying extents.

This in vivo study compared the anti-tumor efficacy of intraperitoneally applied antibodies (HuCAL® anti-CD38) to the vehicle treatment (PBS). The human antibody hMOR03080 (isotype IgG1) was tested in different amounts and treatment schedules and it is assumed that the human antibodies MOR03077 and MOR03079 would lead to similar results than the tested antibody MOR03080.

Example 12: CD38 cross-linking:

The term “control antibody” as used in connection with the present invention with respect to the specific killing correlated with CD38 cross-linking refers to any antibody which is capable of cross-linking CD38. Such antibody may be, for example, an antibody directed

against CD20 or an antibody directed against CD52. Particularly preferred is the commercially available anti-CD20 antibody Rituximab, such as, for example, Rituxan[®] or MabThera[®].

5 Much of the biological activity of antibody therapeutics is attributed to the induction of immune effector function (Ludwig *et al.*, 2003). However, a number of antibodies that are currently in use for hematological malignancies, including anti-CD20 (Shan *et al.*, 2002; Rituximab) and anti-CD52 (Rowan *et al.*, 1998; Alemtuzumab), have shown to induce apoptosis in tumor cells directly by antigen cross-linking and this activity
10 may contribute significantly to their clinical performance. In order to address this question for CD38, a panel of 23 different cell lines (table 7) was subjected to CD38-cross-linking by anti-CD38 antibodies MOR03077, MOR03079, MOR03080, chOKT10. The number of dead cells was calculated at timepoints 0, 4 and 24 hrs in comparison to a negative control antibody (Ly6.3) and the two positive controls anti-CD20 (Rituximab for all cell-lines;
15 Maloney *et al.*, 2002) and anti-MHCII for a selected panel of cell-lines; Nagy *et al.*, 2002). Among the different cell-lines only the 2 out of 3 Burkitt's lymphoma cell-lines, Raji and Namalwa, showed anti-CD38 induced killing. FACS analysis revealed CD38 expression for all lines. CD20 expression was only found on both tested CLL, two of six ALL and all three Burkitt's lymphoma cell lines but killing via anti-CD20 cross-linking was
20 exclusively shown for the Raji cell (table 7). A clear correlation between killing and expression was found for the anti-MHCII antibody, which may be due to a different killing mechanism (table 7). After a 24 hour incubation of Raji cells with anti-CD38 antibodies a mean specific killing of 21% was shown for MOR03077 and MOR03079, whereas the specific killing activity for MOR03080 and OKT10 was only slightly above background
25 levels (4-5%). A specific killing activity of 9% was found for the positive control Rituximab (table 8). Highest specific killing rates of up to 77% were achieved with the anti-MHCII-specific antibody (figure 18). In order to enhance killing efficacy antibody concentrations were increased up to 5-fold of the initial concentration (10 µg/ml) or antibodies given repeatedly several times during the incubation period which was extended
30 up to 168 hrs. Additionally, super cross-linking with an anti-human antibody as described for Rituximab was included in the cytotoxic assays. However, none of those additional parameters led to an increase in specific killing activity for the anti-CD38 or anti-CD20 antibodies (data not shown), which seemed to reach a maximum between 4 and 24 hours

after the addition of antibody. The other Burkitt's lymphoma cell lines were either less sensitive (Namalwa) or did not show any effect (DG-75) despite a comparably high CD38 expression level (table 7). The cytotoxic potential *via* CD38-cross-linking could be confirmed for MOR03077 and MOR03079 on thus far 2-3 different primary MM-samples.

Due to the lack of cells, only specific killing after 4 hrs could be determined. A specific killing of 21 and 24 % could be shown for MOR03077 and MOR03079, respectively, whereas MOR03080 and OKT10 exhibited specific killing just above background levels (4-5; table 8). The data show, that the cytotoxic potential of CD38-antibodies by cross-linking is dependent on the antigenic epitope, which are different for all four antibodies (see also chapter "epitope mapping"). It is known that CD38 must exploit the signalling machinery of other receptors such as CD3, CD19 or MHCII e.g. by specific (lateral) interaction. Thus, depending on the antigenic epitope, the CD38 molecule is cross-linked either together with other co-receptors or differentially exposed for interaction with them in order to trigger a cytotoxic mechanism. Although the CD38-function within lymphopoiesis is not understood, the signalling mechanism may be triggered by its natural ligand on stromal or epithelial cells or, alternatively, by anti-CD38 antibodies. Several *in vitro* studies demonstrated that ligation of CD38 by antibodies can cause a drastic cell reduction including primary CD19⁺ B-cells from normal bone marrow, normal immature myeloid cells and leukemic cells from different ALL-and AML-patients (Kumagai *et al.*, 1995; Todiso *et al.*, 2000). For immature cells, the suppressive effect was more pronounced in the presence of stromal cells (Kumagai *et al.*, 1995) suggesting that a stromal factor renders the cells sensitive to anti-CD38. Although the exact mechanism (growth inhibition or apoptosis) needs to be elucidated, for tumor cells, however, a cytotoxic mechanism seems to be triggered as indicated by the appearance of PI-sensitive cells.

Table 7: Overview characterization of cell-lines for CD38 cross-linking

Cells	Origin	Killing by x-linking of:			Expression of:		
		CD38	CD20	MHCII	CD38	CD20	MHCII
RPM18226	MM	-	-	-	+	-	-
KMS-12-BM		-	-	-	+	-	-
NCI-H929		-	-	-	+	-	-
OPM-2		-	-	-	+	-	-
KMS-11		-	-	+	+	-	+
LP-1		-	-	+	+	-	+
U266		-	-	+/-	+/-	-	+
JVM-13	CLL	-	-	+	+	+	+
JVM-2		-	-	+	+	+	+

CCRF-CEM	ALL	-	-	-	+	-	-
Jurkat		-	-	-	+	-	-
NALM-6		-	-	n.d.	+	-	n.d.
MOLT-4		-	-	n.d.	+	-	n.d.
REH		-	-	n.d.	+	-	n.d.
RS4;11		-	-	n.d.	+	-	n.d.
AML-193	AML	-	-	-	+	+/-	-
OCI-AML5		-	-	-	+	-	+
NB-4		-	-	+/-	+	+/-	+/-
THP-1		-	-	-	+	n.d.	n.d.
HL-60		-	-	-	+	-	-
Raji	Burkitt's lymph.	+	+/-	+	+	+	+
Namalwa		+	-	n.d.	+	+/-	n.d.
DG-75		-	-	n.d.	+	+/-	n.d.

+: positive in expression or killing; +/-: weak in expression or killing; -: negative in expression or killing;
n.d.: not determined

5

Table 8: Specific killing of cell-lines by CD38 cross-linking

Target (EC ₅₀ & spec. killing)	MOR	MOR03	MO	chO	Ritu
	03077	079	R03080	KT10	ximab
Raji (max. spec. killing)^{a,c}:	21 %	21 %	4 %	5 %	9 %
Raji (EC₅₀)^b:	n.d.	0.08 nM	-	n.d.	n.d.
Namalwa (max. spec. Killing)^{b,c}:	11 %	18 %	-	n.d.	-
Namalwa (EC₅₀)^b:	n.d.	0.08 nM	-	n.d.	n.d.
MM-samples (max. spec. Killing)^{b,d}:	21 %	24 %	4 %	5 %	n.d.

- : no effect (specific killing below 1 %)

^a: mean from 7 independent assays

^b: mean from 2-3 independent assays

^c: max. spec. killing after o/n incubation

^d: max. spec. killing after 4hrs incubation

n.d.: not determined

10

15

Table 9: Sequence comparisons (epitope aa 82-94; MOR03080/03100)

CD38 aa pos.	82	83	84	85	86	87	88	89	90	91	92	93	94
Species													
Human	C	Q	S	V	W	D	A	F	K	G	A	F	I
Cynomolgus	C	Q	S	V	W	D	A	F	K	G	A	F	I
Rat	C	K	K	I	L	S	T	F	K	R	G	F	I
Mouse	C	Q	E	I	L	S	T	F	K	G	A	F	V
Rabbit	C	K	K	I	L	N	T	F	T	S	A	F	V
Dog	C	Q	K	I	G	K	A	F	T	S	A	F	L

5

Table 10: Sequence comparisons (epitope aa 158-170; MOR03080)

CD38 aa pos.	158	159	160	161	162	163	164	165	166	167	168	169	170
Species													
Human	T	W	C	G	E	F	N	T	S	K	I	N	Y
Cynomolgus	T	W	C	G	E	F	N	T	F	E	I	N	Y
Rat	R	W	C	G	D	P	S	T	S	D	M	N	Y
Mouse	R	W	C	G	D	P	S	T	S	D	M	N	Y
Rabbit	V	M	C	G	D	P	R	T	S	E	V	K	E
Dog	K	W	C	G	D	T	S	S	S	E	M	N	Y

10 **Table 11: Sequence comparisons (epitope aa 280-296; MOR03100/OKT10)**

CD38 aa pos.	280	281	282	283	284	285	286	287	288	289	290	291	292	293	294	295	296	297	298
Species																			
Human	R	P	D	K	F	L	Q	C	V	K	N	P	E	D	S	S	C	T	S
Cynomolgus	R	P	D	K	F	L	Q	C	V	K	N	P	E	D	S	S	C	L	S
Rat	R	P	V	R	F	L	Q	C	V	K	N	P	E	H	P	S	C	R	L
Mouse	R	P	A	R	F	L	Q	C	V	K	N	P	E	H	P	S	C	R	L
Rabbit	R	P	A	R	F	V	Q	C	V	R	H	P	E	H	P	S	C	S	V
Dog	R	P	V	R	L	L	Q	C	V	K	N	P	E	H	S	S	C	K	Y

Table 12: Sequence comparisons (epitope aa 192-206; MOR03079)

CD38 aa pos: Species	192	193	194	195	196	197	198	199	200	201	202	203	204	205	206
Human	V	S	R	R	F	A	E	A	A	C	D	V	V	H	V
Cynomolgus	V	S	R	R	F	A	E	T	A	C	G	V	V	H	V
Rat	I	S	Q	K	F	A	E	D	A	C	G	V	V	Q	V
Mouse	I	S	Q	K	F	A	E	D	A	C	G	V	V	Q	V
Rabbit	V	S	R	K	F	A	E	S	A	C	G	T	V	Y	V
Dog	V	S	K	R	F	A	E	D	A	C	G	V	V	H	V

Table 13: EC₅₀ in ADCC and CDC

Antibody Targets	ADCC EC ₅₀ values in [nM]			CDC EC ₅₀ values in [nM]
	LP-1	RPMI8226 ^b	MM Samples ^e	CHO hCD38-transfectants
MOR03077	0.60 ^b	0.08	0.08	0.94 ^c
MOR03079	0.09 ^b	0.04	0.112 - 0.202	0.41 ^b
MOR03080	0.17 ^a	0.05	0.006 - 0.185	2.93 ^c
MOR03100	1.00 ^a	0.28	0.03 - 0.252	13.61 ^d
chOKT10	5.23 ^b	4.1	0.301 - 0.356	9.3 ^b

^a: single determination^b: mean from 2 independent EC₅₀ determinations^c: mean from 3 independent EC₅₀ determinations^d: mean from 4 independent EC₅₀ determinations^e: range from at least 2 independent EC₅₀ determinations; purified primary MM-cells

Table 14: IHC and FACS-analysis on normal human cells and tissues

Antibody & Analysis Tissues	MOR03077	MOR03079	MOR03080	MOR03100	OKT10	Analysis
Erythrocytes	-	+/-	-	-	-	FACS
Lymphocytes	+	+	+	+	+	FACS
Thymocytes	+	+	+	+	+	FACS
Muscle	-	-	-	-	-	IHC
Cerebellum	+/-	+/-	+/-	+/-	++	IHC
Pancreas	-	-	-	++	-	IHC
Lymph-nodes	-	+	+	+	+	IHC
Tonsils	+	+	+	+	+	IHC
Spleen	+	+	+	+	+	IHC
Prostate	+	+	+	+	+	IHC
Skin	-	-	-	-	-	IHC

++: strong positive staining

+: positive staining

+/-: weak positive staining

IHC : use of cryo-conserved tissue

5 References:

Antonelli, A., Baj, G., Marchetti, P., Fallahi, P., Surico, N., Pupilli, C., Malavasi, F., Ferrannini, P. (2001). Human anti-CD38 autoantibodies raise intracellular calcium and stimulate insulin release in human pancreatic islets. *Diabetes* 50: 985-991

Ausiello C.M., Urbani F., Lande R., la Sala A., Di Carlo B., Baj G., Surico N., Hilgers J., Deaglio S., Funaro A., Malavasi F. (2000) Functional topography of discrete domains of human CD38. *Tissue Antigens*. 2000 Dec;56(6):539-47.

Chamow, S.M., Zhang, D.Z., Tan, X.Y, Mathre, S.M., Marsters, S.A., Peers, D.H., Byrn, R.A., Ashknazi, A., Junghans, R.P (1994). humanized, bispecific immunoadhesin-antibody that retargets CD3+ effectors to kill HIV-1-infected cells. *J Immunol*. 1994 Nov 1;153(9):4268-80

Dattamajumdar, A.K., Jacobsen, D.P., Hood, L.E., Osman, G.E. (1996). Rapid cloning of rearranged mouse immunoglobulin variable genes. *Immunogenetics* 43, 141-151

Ellis J. H., Barber, K. A., Tutt, A., Hale, C., Lewis, A. P., Glennie, M. J., Stevenson, G. T., and Crowe, J. (1995). Engineered anti-CD38 monoclonal antibodies for immunotherapy of multiple myeloma. *J. Immunol*. 155:925-937.

Ferrero, E., Orciani, M., Vacca, P., Ortolan, E., Crovella, S., Titti, F., Saccucci, F., Malavasi, F. (2004). Characterization and phylogenetic epitope mapping of CD38 ADPR cyclase in the cynomolgus macaque. *BMC Immunology* 5:21

Flavell, D. J., Boehm, D. A., Noss, A., Warnes, S. L., and Flavell, S. U. Therapy of human T-cell acute lymphoblastic leukaemia with a combination of anti-CD7 and anti-CD38-saporin immunotoxins is significantly better than therapy with each individual immunotoxin, *Br. J. Cancer*. 84:571-578 (2001).

5

Funaro, A., Spagnoli, G.C., Ausiello, C.M., Alessio, M., Roggero, S., Delia, D., Zaccolo, M., and Malavasi, F. (1990) Involvement of the multilineage CD38 molecule in a unique pathway of cell activation and proliferation. *J. Immunol.* 145, 2390-2396.

10 Golay, J., Zaffaroni, Luisella, Vaccari, T., Lazzari, M., Borleri, G.-M., Bernasconi, S., Tedesco, F., Rambaldi, Al, Introna, M. (2000). Biological response of B lymphoma to anti-CD20 monoclonal antibody in vitro: CD55 and CD59 regulate complement-mediated cell lysis. *Blood* 95: 3900-3908.

15 Hayashi, T., Treon, S.P., Hideshima, T., Tai, Y-T., Akiyama, M., Richardson, R., Chauhan, D., Grewal, I.S., Anderson, K.C. (2003). Recombinant humanized anti-CD40 monoclonal antibody triggers autologous antibody-dependent cell-mediated cytotoxicity against multiple myeloma. *Br. J. Hematol.* 121, 592-596.

20 Hoshino S., Kukimoto I., Kontani K., Inoue S., Kanda Y., Malavasi F., Katada T. (1997) Mapping of the catalytic and epitopic sites of human CD38/NAD⁺ glycohydrolase to a functional domain in the carboxyl terminus. *J Immunol.* 158(2):741-7.

25 Jackson D.G., Bell J.I. (1990) Isolation of a cDNA encoding the human CD38 (T10) molecule, a cell surface glycoprotein with an unusual discontinuous pattern of expression during lymphocyte differentiation. *J Immunol.* 144(7):2811-5.

30 Knappik, A., Ge, L., Honegger, A., Pack, P., Fischer, M., Wellnhofer, G., Hoess, A., Wolle, J., Pluckthun, A., and Virnekas, B. (2000). Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides. *J Mol Biol* 296, 57-86.

35 Kono, K., Takahashi, A., Ichihara, F., Sugai, H., Fujii, H., and Matsumoto, Y. (2002). Impaired antibody-dependent cellular cytotoxicity mediated by Herceptin in patients with gastric cancer. *Cancer Res.* 62, 5813-5817.

40 Konopleva M., Estrov Z., Zhao S., Andreeff M., Mehta K. (1998) Ligation of cell surface CD38 protein with agonistic monoclonal antibody induces a cell growth signal in myeloid leukemia cells. *J Immunol.* 161(9):4702-8.

Krebber, A., Bornhauser, S., Burmester, J., Honegger, A., Willuda, J., Bossard, H.R., Plückthun, A. (1997). Reliable cloning of functional antibody variable domains from hybridomas and spleen cell repertoires employing a reengineered phage display system. *J. Imm. Meth.* 201, 35-55.

45 Krebs, B., Rauchenberger, R., Reiffert, S., Rothe, C., Tesar, M., Thomassen, E., Cao, M., Dreier, T., Fischer, D., Hoss, A., Inge, L., Knappik, A., Marget, M., Pack, P., Meng, X.Q., Schier, R., Sohlmann, P., Winter, J., Wolle, J., and Kretzschmar, T. (2001). High-throughput generation and engineering of recombinant human antibodies. *J Immunol Methods* 254, 67-84.

50

Löhning, C. (2001). Novel methods for displaying (poly)peptides/proteins on bacteriophage particles via disulfide bonds. WO 01/05950.

Malavasi, F., Caligaris-Cappio, F., Milanese, C., Dellabona, P., Richiardi, P., Carbonara, A. O. (1984). Characterization of a murine monoclonal antibody specific for human early lymphohemopoietic cells. *Hum. Immunol.* 9: 9-20

Maloney, D. G., Smith, B., and Rose, A. (2002). Rituximab: Mechanism of Action and Resistance. *Sem. Oncol.* 29, 2-9.

Marchetti, P., Antonelli, A., Lupi, R., Marselli, L., Fallahi, P., Nesti, C., Baj, G., Ferrannini, E. (2002). Prolonged in vitro exposure to autoantibodies against CD38 impairs the function and survival of human pancreatic islets. *Diabetes* 51, 474-477.

Mehta, K., Ocanas, L., Malavasi, f., Marks; J.W., Rosenblum, M.G (2004). Retinoic acid-induced CD38 antigen as a target for immunotoxin-mediated killing of leukemia cells. *Mol. Cancer Ther.* 3, 345-352

Namba, M., Otsuki, T., Mori, M., Togawa, A., Wada, H., Sugihara, T., Yawata, Y., Kimoto, T. (1989). Establishment of five human myeloma cell lines. *In Vitro Cell Dev. Biol.* 25: 723.

Nata K., Takamura T., Karasawa T., Kumagai T., Hashioka W., Tohgo A., Yonekura H., Takasawa S., Nakamura S., Okamoto H. (1997). Human gene encoding CD38 (ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase): organization, nucleotide sequence and alternative splicing. *Gene* 186(2):285-92.

Naundorf, S., Preithner, S., Mayer, P., Lippold, S., Wolf, A., Hanakam, F., Fichtner, I., Kufer, P., Raum, T., Riethmüller, G., Baeuerle, P.A., Dreier, T. (2002). *Int. J. Cancer* 100, 101-110.

Plückthun A, and Pack P. (1997) New protein engineering approaches to multivalent and bispecific antibody fragments. *Immunotechnology* 3(2):83-105.

Rauchenberger R., Borges E., Thomassen-Wolf E., Rom E., Adar R., Yaniv Y., Malka M., Chumakov I., Kotzer S., Resnitzky D., Knappik A., Reiffert S., Prassler J., Jury K., Waldherr D., Bauer S., Kretzschmar T., Yayon A., Rothe C. (2003). Human combinatorial Fab library yielding specific and functional antibodies against the human fibroblast growth factor receptor 3. *J Biol Chem.* 278(40):38194-205.

Reff, M.E., Carner, K., Chambers, K.S., Chinn, P.C., Leonard, J.E., Raab, R., Newman, R.A., Hanna, N., Anderson, D.R. (1994). Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. *Blood* 83: 435-445

Santin, A.D., Bellone, S., Gokden, M., Palmieri, M., Dunn, D., Agha, J., Roman, J.J., Hutchins, L., Pecorelli, S., O'Brian, T., Cannon, M.J., Parham, G.P. (2002). Overexpression of HER-2/Neu in Uterine serous papillary cancer. *Cl. Cancer Res.* 8: 1271-1279.

Shinkawa, T., Nakamura, K., Yamane, N., Shoji-Hosaka, E., Kanda, Y., Sakurada, M.,
Uchida, K., Anazawa, H., Satoh, M., Yamasaki, M., Hanai, N., Shitara, K. (2003). The
absence of fucose but Not the presence of galactose or bisectin N-Acetylglucosamine of
5 human IgG1 complex-type oligosaccharides shows the critical role of enhancing
antibody-dependent cellular cytotoxicity. J. Biol. Chem. 278, 3466-3473.

Zhou, H., Fisher, R.J., Papas, T.S. (1994). Optimization of primer sequences for mouse
scFv repertoire display library construction. Nucleic Acids Res. 22: 888-889.

10

15

CLAIMS

1. A method of inducing specific killing of tumor cells that express CD38,
5 wherein said specific killing occurs by CD38 cross-linking, comprising the steps of:
- (i) incubating said cells in the presence of (a) a sufficient amount of a human or humanized anti-CD38 antibody or a functional fragment thereof and (b) a control antibody designated as anti-CD20 under
10 conditions that permit cross-linking, and
- (ii) detecting the specific killing activity of said human or humanized anti-CD38 antibody or said functional fragment thereof, wherein said specific killing activity is at least 2-fold, 3-fold, 4-fold or 5-fold better than the specific killing activity of said control antibody.
- 15
2. A method according to claim 1, wherein said human or humanized anti-CD38 antibody or said functional fragment thereof comprises a nucleic acid sequence encoding a heavy chain depicted in SEQ ID NO: 1, 2, 3 or 4; and/or a nucleic acid sequence encoding a light chain depicted in SEQ ID
20 NO: 9, 10, 11 or 12.
3. A method according to claim 1, wherein said human or humanized anti-CD38 antibody or said functional fragment thereof comprises a heavy chain amino acid sequence depicted in SEQ ID NO: 5, 6, 7 or 8; and/or a light
25 chain amino acid sequence depicted in SEQ ID NO: 13, 14, 15 or 16.

4. A method of inducing specific killing of tumor cells that express CD38, by CD38 cross-linking, comprising the steps of:

- (i) administering to a subject in need thereof an effective amount of a human or humanized anti-CD38 antibody or a functional fragment thereof, and
- (ii) detecting the specific killing activity of said human or humanized anti-CD38 antibody or said functional fragment thereof.

5. A method according to claim 4, wherein said tumor cells are of human, minipig or rabbit origin.

6. A method of detecting the presence of CD38 in a tissue or a cell of minipig origin, comprising the steps of:

- (i) allowing a human or humanized anti-CD38 antibody or a functional fragment thereof to come into contact with said CD38, and
- (ii) detecting the specific binding of said human or humanized anti-CD38 antibody or functional fragment thereof to said CD38 minipig cells, wherein said antibody or functional fragment thereof is also able to specifically bind to CD38 of human origin.

7. A method according to claim 6, wherein said CD38 of minipig origin is comprised within an isolated cell type selected from the group consisting of peripheral blood monocyte, erythrocyte, lymphocyte, thymocyte, muscle cell, cerebellum cell, pancreas cell, lymph-node cell, tonsil cell, spleen cell, prostate cell, skin cell and a cell of the retina.

8. A method according to claim 6, wherein said human or humanized anti-CD38 antibody or functional fragment thereof comprises (i) a nucleic acid sequence encoding a heavy chain depicted in SEQ ID NO: 1 and/or a nucleic acid sequence encoding a light chain depicted in SEQ ID NO: 9; or
- 5 (ii) a sequence having at least 60 percent identity in the heavy chain regions depicted in SEQ ID NO: 1 and/or a sequence having at least 60 percent identity in the light chain regions depicted in SEQ ID NO: 9.
9. A method according to claim 6, wherein said human or humanized anti-
- 10 CD38 antibody or functional fragment thereof comprises (i) a heavy chain amino acid sequence depicted in SEQ ID NO: 5 and/or a light chain amino acid sequence depicted in SEQ ID NO: 13; or (ii) a sequence having at least 60 percent identity in the heavy chain regions depicted in SEQ ID NO: 5 and/or a sequence having at least 60 percent identity in the light chain
- 15 regions depicted in SEQ ID NO: 13.
10. A method of detecting CD38 in a CD38-expressing erythrocyte, comprising the steps of:
- (i) allowing a human or humanized anti-CD38 antibody or a functional
- 20 fragment thereof to come into contact with said CD38-expressing erythrocyte, and
- (ii) detecting the specific binding of said human or humanized anti-CD38 antibody or functional fragment thereof to said CD38-expressing erythrocytes, wherein said antibody or functional fragment thereof is
- 25 also able to specifically bind to human CD38 from a cell or tissue other than human erythrocytes.

11. A method according to claim 10, wherein said antibody or functional fragment thereof is also able to specifically bind to human CD38 from a cell that is a human lymphocyte.

5

12. A method according to claim 10, wherein said human or humanized anti-CD38 antibody or functional fragment thereof comprises (i) a nucleic acid sequence encoding a heavy chain depicted in SEQ ID NO: 2 or 3 and/or a nucleic acid sequence encoding a light chain depicted in SEQ ID NO: 10 or 11; or (ii) a sequence having at least 60 percent identity in the heavy chain regions depicted in SEQ ID NO 2 or 3 and a sequence having at least 60 percent identity in the light chain regions depicted in SEQ ID NO: 10 or 11.

10

13. A method according to claim 10, wherein said human or humanized anti-CD38 antibody or functional fragment thereof comprises (i) a heavy chain amino acid sequence depicted in SEQ ID NO: 6 or 7 and/or a light chain amino acid sequence depicted in SEQ ID NO: 14 or 15; or (ii) a sequence having at least 60 percent identity in the heavy chain regions depicted in SEQ ID NO 6 or 7 and a sequence having at least 60 percent identity in the light chain regions depicted in SEQ ID NO: 14 or 15.

15

20

14. A method according to any one of claims 1 to 5 wherein said specific killing which occurs by CD38 cross-linking additionally is caused by antibody-dependent cellular cytotoxicity and/or complement-dependent cytotoxicity

25

Figure 1a**Variable Heavy Chain DNA****3077_VH1B (SEQ ID NO: 1):**

5 (1) CAGGTGCAAT TGGTTCAGAG CGGCGCGGAA GTGAAAAAAC CGGGCGCGAG
 (51) CGTGAAAGTG AGCTGCAAAG CCTCCGGATA TACCTTTACT TCTTATTCTA
 (101) TTAATTGGGT CCGCCAAGCC CCTGGGCAGG GTCTCGAGTG GATGGGCTAT
 (151) ATCGATCCGA ATCGTGCGAA TACGAATTAC GCGCAGAAGT TTCAGGGCCG
 (201) GGTGACCATG ACCCGTGATA CCAGCATTAG CACCGCGTAT ATGGAACTGA
 10 (251) GCAGCCTGCG TAGCGAAGAT ACGGCCGTGT ATTATTGCGC GCGTGAGTAT
 (301) ATTTATTTTA TTCATGGTAT GCTTGATTTT TGGGGCCAAG GCACCCTGGT
 (351) GACGGTTAGC TCA

3079_VH3 (SEQ ID NO: 2):

15 (1) CAGGTGCAAT TGGTGGAAG CGGCGGCGGC CTGGTGCAAC CGGGCGGCAG
 (51) CCTGCGTCTG AGCTGCGCGG CCTCCGGATT TACCTTTTCT AATTATGGTA
 (101) TGCATTGGGT GCGCCAAGCC CCTGGGAAGG GTCTCGAGTG GGTGAGCAAT
 (151) ATCCGTTCTG ATGGTAGCTG GACCTATTAT GCGGATAGCG TGAAAGGCCG
 20 (201) TTTTACCATT TCACGTGATA ATTCGAAAAA CACCCTGTAT CTGCAATGA
 (251) ACAGCCTGCG TGCGGAAGAT ACGGCCGTGT ATTATTGCGC GCGTCGTTAT
 (301) TGGTCTAAGT CTCATGCTTC TGTTACTGAT TATTGGGGCC AAGGCACCCT
 (351) GGTGACGGTT AGCTCA

3080_VH3 (SEQ ID NO: 3):

25 (1) CAGGTGCAAT TGGTGGAAG CGGCGGCGGC CTGGTGCAAC CGGGCGGCAG
 (51) CCTGCGTCTG AGCTGCGCGG CCTCCGGATT TACCTTTTCT TCTTATGGTA
 (101) TGCATTGGGT GCGCCAAGCC CCTGGGAAGG GTCTCGAGTG GGTGAGCAAT
 30 (151) ATCTATTCTG ATGGTAGCAA TACCTTTTAT GCGGATAGCG TGAAAGGCCG
 (201) TTTTACCATT TCACGTGATA ATTCGAAAAA CACCCTGTAT CTGCAATGA
 (251) ACAGCCTGCG TGCGGAAGAT ACGGCCGTGT ATTATTGCGC GCGTAATATG
 (301) TATCGTTGGC CTTTTCATTA TTTTTTTGAT TATTGGGGCC AAGGCACCCT
 (351) GGTGACGGTT AGCTCA

3100_VH 3 (SEQ ID NO: 4):

35 (1) CAGGTGCAAT TGGTGGAAG CGGCGGCGGC CTGGTGCAAC CGGGCGGCAG
 (51) CCTGCGTCTG AGCTGCGCGG CCTCCGGATT TACCTTTTCT TCTAATGGTA
 40 (101) TGTCTTGGGT GCGCCAAGCC CCTGGGAAGG GTCTCGAGTG GGTGAGCAAT
 (151) ATCTCTTATC TTTCTAGCTC TACCTATTAT GCGGATAGCG TGAAAGGCCG
 (201) TTTTACCATT TCACGTGATA ATTCGAAAAA CACCCTGTAT CTGCAATGA
 (251) ACAGCCTGCG TGCGGAAGAT ACGGCCGTGT ATTATTGCGC GCGTTTTTAT
 (301) GGTTATTTTA ATTATGCTGA TGTTTGGGGC CAAGGCACCC TGGTGACGGT
 45 (351) TAGCTCA

3077_1_VH1B (SEQ ID NO: 31):

(1) CAGGTGCAAT **TAGTCCAAAG** **TGGT**GCGGAA GTGAAAAAAC CGGGCGCGAG
 50 (51) CGTGAAAGTG AGCTGCAAAG CCTCCGGATA TACCTTTACT TCTTATTCTA
 (101) TTAATTGGGT CCGCCAAGCC CCTGGGCAGG GTCTCGAGTG GATGGGCTAT

(151) ATCGATCCGA ATCGTGGCAA TACGAATTAC GCGCAGAAGT TTCAGGGCCG
(201) GGTGACCATG ACCCGTGATA CCAGCATTAG CACCGCGTAT ATGGAACTGA
(251) GCAGCCTGCG TAGCGAAGAT ACGGCCGTGT ATTATTGCGC GCGTGAGTAT
(301) ATTTATTTTA TTCATGGTAT GCTTGATTTT TGGGGCCAAG GCACCCTGGT
5 (351) GACGGTTAGC TCA

Figure 1b**Variable Heavy Chain Peptide**(CDR Regions in **Bold**)5 **3077_VH1B** (SEQ ID NO: 5):

(1) QVQLVQSGAE VKKPGASVKV SCKAS**GYTFT** **SYSIN**WVRQA PGQGLEWMGY
(51) **IDPNRGNTNY** **AQKFQGR**VTM TRDTSISTAY MELSSLRSED TAVYYCARE**Y**
(101) **IYFIHGMLDF** WGQGTLVTVS S

10

3079_VH3 (SEQ ID NO: 6):

(1) QVQLVESGGG LVQPGGSLRL SCAAS**GFTFS** **NYGMH**WVRQA PGKGLEWV**SN**
(51) **IRSDGSWTYY** **ADSVKGR**FTI SRDNSKNTLY LQMNSLRAED TAVYYCARR**Y**
(101) **WSKSHASVTD** YWGQGTLVTV SS

15

3080_VH3 (SEQ ID NO: 7):

(1) QVQLVESGGG LVQPGGSLRL SCAAS**GFTFS** **SYGMH**WVRQA PGKGLEWV**SN**
(51) **IYSDGSNTFY** **ADSVKGR**FTI SRDNSKNTLY LQMNSLRAED TAVYYCARN**M**
(101) **YRWPFHYFFD** YWGQGTLVTV SS

20

3100_VH 3 (SEQ ID NO: 8):

(1) QVQLVESGGG LVQPGGSLRL SCAAS**GFTFS** **SNGMS**WVRQA PGKGLEWV**SN**
(51) **ISYLSSTYY** **ADSVKGR**FTI SRDNSKNTLY LQMNSLRAED TAVYYCAR**FY**
(101) **GYFNYADVWG** QGTLVTVSS

25

Figure 2a**Variable Light Chain DNA****3077_Vk kappa 2 (SEQ ID NO: 9):**

```

5   (1)   GATATCGTGA TGACCCAGAG CCCACTGAGC CTGCCAGTGA CTCCGGGCGA
    (51)  GCCTGCGAGC ATTAGCTGCA GAAGCAGCCA AAGCCTGCTT TTTATTGATG
    (101) GCAATAATTA TCTGAATTGG TACCTTCAAA AACCAGGTCA AAGCCCGCAG
    (151) CTATTAATTT ATCTTGGTTC TAATCGTGCC AGTGGGGTCC CGGATCGTTT
    (201) TAGCGGCTCT GGATCCGGCA CCGATTTTAC CCTGAAAATT AGCCGTGTGG
10  (251) AAGCTGAAGA CGTGGGCGTG TATTATTGCC AGCAGTATTC TTCTAAGTCT
    (301) GCTACCTTTG GCCAGGGTAC GAAAGTTGAA ATTAAACGTA CG

```

3079_Vk kappa 1 (SEQ ID NO: 10):

```

15  (1)   GATATCCAGA TGACCCAGAG CCCGTCTAGC CTGAGCGCGA GCGTGGGTGA
    (51)  TCGTGTGACC ATTACCTGCA GAGCGAGCCA GGATATTTCT GCTTTTCTGA
    (101) ATTGGTACCA GCAGAAACCA GGTAAAGCAC CGAAACTATT AATTTATAAG
    (151) GTTTCTAATT TGCAAAGCGG GGTCCCCTCC CGTTTTAGCG GCTCTGGATC
    (201) CGGCACTGAT TTTACCCTGA CCATTAGCAG CCTGCAACCT GAAGACTTTG
20  (251) CGACTTATTA TTGCCAGCAG GCTTATTCTG GTTCTATTAC CTTTGGCCAG
    (301) GGTACGAAAG TTGAAATTAA ACGTACG

```

3080_VI lambda 3 (SEQ ID NO: 11):

```

25  (1)   GATATCGAAC TGACCCAGCC GCCTTCAGTG AGCGTTGCAC CAGGTCAGAC
    (51)  CGCGCGTATC TCGTGTAGCG GCGATAATAT TGGTAATAAG TATGTTTCTT
    (101) GGTACCAGCA GAAACCCGGG CAGGCGCCAG TTGTTGTGAT TTATGGTGAT
    (151) AATAATCGTC CCTCAGGCAT CCCGGAACGC TTTAGCGGAT CCAACAGCGG
    (201) CAACACCGCG ACCCTGACCA TTAGCGGCAC TCAGGCGGAA GACGAAGCGG
30  (251) ATTATTATTG CTCTTCTTAT GATTCTTCTT ATTTTGTGTT TGGCGGCGGC
    (301) ACGAAGTTAA CCGTTCTTGG CCAG

```

3100_VI lambda 3 (SEQ ID NO: 12):

```

35  (1)   GATATCGAAC TGACCCAGCC GCCTTCAGTG AGCGTTGCAC CAGGTCAGAC
    (51)  CGCGCGTATC TCGTGTAGCG GCGATAATAT TGGTCATTAT TATGCTTCTT
    (101) GGTACCAGCA GAAACCCGGG CAGGCGCCAG TTCTTGTGAT TTATCGTGAT
    (151) AATGATCGTC CCTCAGGCAT CCCGGAACGC TTTAGCGGAT CCAACAGCGG
    (201) CAACACCGCG ACCCTGACCA TTAGCGGCAC TCAGGCGGAA GACGAAGCGG
40  (251) ATTATTATTG CCAGTCTTAT GATTATCTTC ATGATTTTGT GTTTGGCGGC
    (301) GGCACGAAGT TAACCGTTCT TGGCCAG

```

45

Figure 2b**Variable Light Chain Peptide**(CDR Regions in **Bold**)5 **3077_Vk kappa 2** (SEQ ID NO: 13):

(1) DIVMTQSPLS LPVTPGEPAS ISCRSS**QSLL FIDGNNYLNW** YLQKPGQSPQ
(51) LLI**YLGSNRA** SGVPDRFSGS GSGTDFTLKI SRVEAEDGVV YYC**QQYSSKS**
(101) **ATFGQGTKVE** IKRT

10

3079_Vk kappa 1 (SEQ ID NO: 14):

(1) DIQMTQSPSS LSASVGDRVT ITCRAS**QDIS AFLN**WYQQKP GKAPKLLI**YK**
(51) **VSNLQ**SGVPS RFSGSGSGTD FTLTISSLQP EDFATYYC**QQ** **AYSGS**ITFGQ
(101) GTKVEIKRT

15

3080_Vl lambda 3 (SEQ ID NO: 15):

(1) DIELTQPPSV SVAPGQTARI SCS**GDNIGNK YV**SWYQQKPG QAPVVVIY**GD**
(51) **NNRPS**GIPER FSGSNSGNTA TLTISGTQAE DEADYYC**SSY DSSYF**VFGG
(101) TKLTVLGQ

20

25

3100_Vl lambda 3 (SEQ ID NO: 16):

(1) DIELTQPPSV SVAPGQTARI SCS**GDNIGHY YAS**WYQQKPG QAPVLVIY**RD**
(51) **NDRPS**GIPER FSGSNSGNTA TLTISGTQAE DEADYYC**QSY DYLHDF**VFGG
(101) GTKLTVLGQ

30

Figure 3**Variable Heavy Chain Consensus Sequences**(CDR Regions in **Bold**)5 **VH1B Consensus (SEQ ID NO: 17):**

(1) QVQLVQSGAE VKKPGASVKV SCKAS**GYTFT** **SYMH**WVRQA PGQGLEWMGW
(51) **INPNSGGTNY** **AQKFQGRVTM** TRDTSISTAY MELSSLRSED TAVYYCAR**WG**
(101) **GDGFYAMDYW** GQGTLVTVSS

10

VH3 Consensus (SEQ ID NO: 18):

(1) QVQLVESGGG LVQPGGSLRL SCAAS**GFTFS** **SYAMS**WVRQA PGKGLEWV**SA**
15 (51) **ISGSGGSTYY** **ADSVKGRFTI** SRDNSKNTLY LQMNSLRAED TAVYYCAR**WG**
(101) **GDGFYAMDYW** GQGTLVTVS S

15

Figure 4**Variable Light Chain Consensus Sequences**(CDR Regions in **Bold**)**VL_λ3 Consensus** (SEQ ID NO: 19):

(1) SYELTQPPSV SVAPGQTARI **SCSGDALGDK** **YASWYQQKPG** QAPVLVIY**DD**
(51) **SDRPS**GIPER FSGSNSGNTA TLTISGTQAE DEADYYC**QQH** **YTTP**PVFGGG
(101) TKLTVLG

VL_k1 Consensus (SEQ ID NO: 20):

(1) DIQMTQSPSS LSASVGDRVIT **ITCRASQGIS** **SYLAWYQQKP** GKAPKLLI**YA**
(51) **ASSLQ**SGVPS RFSGSGSGTD FTLTISSLQP EDFATYYC**QQ** **HYTTP**PFTFGQ
(101) GTKVEIKR

VL_k2 Consensus (SEQ ID NO: 21):

(1) DIVMTQSPLS LPVTPGEPAS **ISCRSSQSLL** **HSNGYNYLDW** YLQKPGQSPQ
(51) LLIY**LGSNRA** **SGVPDR**FSGS GSGTDFTLKI SRVEAEDVGV YYC**QQHYTTP**
(101) PTFGQGTKVE IKR

Figure 5**Peptide Sequence of CD38**

(SEQ ID NO: 22):

```
1      mancefspvs gdkpccrlsr raqlclgvs lvlilvvla vvpwrwqqw sgpgttkrpf
5 61    etvlarcvky teihpemrhv dcqsvwdafk gafiskhpcn iteedyqplm klgtqtvpcn
121   killwsrikd lahqftqvqr dmftledtll gyladdltwc gefntskiny qscpdwrkdc
181   snnpvsvfwk tvsrrfaaaa cdvvhvmlng srskifdkns tfgsvevhnl qpekvtlea
241   wvihggreds rdlcqdptik elesiiskrn iqfsckniyr pdkflqcvkn pedssctsei
```

Figure 6**Nucleotide Sequence of Chimeric OKT10****Heavy Chain (SEQ ID NO: 23):**

caggtggaat tgggtggaatc tggaggatcc ctgaaactct cctgtgcagc ctcaggattc
 5 gatttttagta gatcctggat gaattgggtc cggcaggctc caggaaaagg gctagaatgg
 attggagaaa ttaatccaga tagcagtacg ataaactata cgacatctct aaaggataaa
 ttcatcatct ccagagacaa cgccaaaaat acgctgtacc tgcaaatgac caaagtgaga
 tctgaggaca cagcccttta ttactgtgca agatatggta actggtttcc ttattggggc
 caagggactc tggtcactgt cagctcagcc tccaccaagg gtccatcggg cttccccctg
 10 gcaccctcct ccaagagcac ctctgggggc acagcggccc tgggctgcct ggtcaaggac
 tacttccccg aaccggtgac ggtgtcgtgg aactcaggcg ccctgaccag cggcgtgcac
 accttccccg ctgtcctaca gtctcagga ctctactccc tcagcagcgt ggtgaccgtg
 ccctccagca gcttgggcac ccagacctac atctgcaacg tgaatcaciaa gcccagcaac
 accaaggtgg acaagaaagt tgagcccaaa tcttgtgaca aaactcacac atgcccaccg
 15 tgcccagcac ctgaactcct ggggggaccg tcagtcttcc tcttcccccc aaaacccaag
 gacaccctca tgatctcccc gaccctgag gtcacatgcg tgggtggtgga cgtgagccac
 gaagaccctg aggtcaagtt caactggtac gtggacggcg tggaggtgca taatgccaag
 acaaagccgc gggaggagca gtacaacagc acgtaccggg tggtcagcgt cctcaccgtc
 ctgcaccagg actggctgaa tggcaaggag tacaagtgca aggtctccaa caaagccctc
 20 ccagccccca tcgagaaaac catctccaaa gccaaagggc agccccgaga accacaggtg
 tacaccctgc ccccatcccc ggatgagctg accaagaacc aggtcagcct gacctgcctg
 gtcaaaggct tctatcccag cgacatcgcc gtggagtggg agagcaatgg gcagccggag
 aacaactaca agaccacgcc tcccgtgctg gactccgacg gtccttctt cctctacagc
 aagctcaccg tggacaagag caggtggcag caggggaacg tcttctcatg ctccgtgatg
 25 catgaggctc tgcacaacca ctacacgcag aagagcctct ccctgtctcc gggtaaa

Light Chain (SEQ ID NO: 24):

gatatcctga tgaccagtc tcaaaaaatc atgccacat cagtgggaga cagggtcagc
 gtcacctgca aggccagtca aaatgtggat actaatgtag cctggtatca acagaaacca

ggacagtctc ctaaagcaact gatttactcg gcatacctacc gatacagtgg agtcacctgat
cgcttcacag gcagtggtatc tgggacagat ttcaactctca ccatcaccaa tgtgcagtct
gaggacttgg cagagtattt ctgtcagcaa tatgacagct atcctctcac gttcggtgct
gggaccaagc tggacctgaa acgtacggtg gctgcaccat ctgtcttcat cttcccgcca
5 tctgatgagc agttgaaatc tggaactgcc tctgttgtgt gcctgctgaa taacttctat
cccagagagg ccaaagtaca gtggaaggtg gataacgccc tccaatcggg taactcccag
gagagtgtca cagagcagga cagcaaggac agcacctaca gcctcagcag caccctgacg
ctgagcaaag cagactacga gaaacacaaa gtctacgcct gcgaagtcac ccatcagggc
ctgagctcgc ccgtcacaaa gagcttcaac aggggagagt gt

Fig.7: Schematic Overview of Epitopes




Figure 8: DNA sequence of pMOPRH[®]_h_IgG1_1

```

5           StyI
           ~~~~~~
601      TCGCTATTAC CATGGTGATG CGGTTTTTGGC AGTACATCAA TGGGCGTGGA
          AGCGATAATG GTACCACTAC GCCAAAACCG TCATGTAGTT ACCCGCACCT

10                                           AatII
                                           ~~~~~~
651      TAGCGGTTTG ACTCACGGGG ATTTCCAAGT CTCCACCCCA TTGACGTCAA
          ATCGCCAAAC TGAGTGCCCC TAAAGGTTCA GAGGTGGGGT AACTGCAGTT

15      701      TGGGAGTTTG TTTTGGCACC AAAATCAACG GGA CTTTCCA AAATGTCGTA
          ACCCTCAAAC AAAACCGTGG TTTTAGTTGC CCTGAAAGGT TTTACAGCAT

751      ACAACTCCGC CCCATTGACG CAAATGGGCG GTAGGCGTGT ACGGTGGGAG
          TGTTGAGGCG GGGTAACTGC GTTTACCCGC CATCCGCACA TGCCACCCTC

20      801      GTCTATATAA GCAGAGCTCT CTGGCTAACT AGAGAACCCA CTGCTTACTG
          CAGATATATT CGTCTCGAGA GACCGATTGA TCTCTTGGGT GACGAATGAC

25           pMORPH®_Ig_FOR 100.0%           NheI
           ~~~~~~           ~~~~~~
851      GCTTATCGAA ATTAATACGA CTCACTATAG GGAGACCCAA GCTGGCTAGC
          CGAATAGCTT TAATTATGCT GAGTGATATC CCTCTGGGTT CGACCGATCG

30           M K H L W F F L L L V A A P R .
901      GCCACCATGA AACACCTGTG GTTCTTCCTC CTGCTGGTGG CAGCTCCAG
          CGGTGGTACT TTGTGGACAC CAAGAAGGAG GACGACCACC GTCGAGGGTC

35           EcoRI           BspI           StyI
           ~~~~~~           ~~~~~~           ~~~~~~
           A S T .
           . W V L S Q V E F C R R L A Q
951      ATGGGTCCTG TCCCAGGTGG AATTCTGCAG GCGGTTAGCT CAGCCTCCAC
          TACCCAGGAC AGGGTCCACC TTAAGACGTC CGCCAATCGA GTCGGAGGTG

40      StyI           BbsI
      ~~~~~~           ~~~~~~
           . K G P S V F P L A P S S K S T S G .
1001     CAAGGGTCCA TCGGTCTTCC CCCTGGCACC CTCCTCCAAG AGCACCTCTG
          GTTCCCAGGT AGCCAGAAGG GGGACCGTGG GAGGAGGTTC TCGTGGAGAC

45           . G T A A L G C L V K D Y F P E P
1051     GGGGCACAGC GGCCCTGGGC TGCCTGGTCA AGGACTACTT CCCC GAACCG
          CCGGTGTCG CCGGGACCCG ACGGACCACT TCCTGATGAA GGGGCTTGCG

```

1101 V T V S W N S G A L T S G V H T F .
 GTGACGGTGT CGTGGAAGCTC AGGCGCCCTG ACCAGCGGCG TGCACACCTT
 CACTGCCACA GCACCTTGAG TCCGCGGGAC TGGTCGCCGC ACGTGTGGAA
 5
 1151 . P A V L Q S S G L Y S L S S V V T .
 CCCGGCTGTC CTACAGTCTT CAGGACTCTA CTCCCTCAGC AGCGTGGTGA
 GGGCCGACAG GATGTCAGGA GTCCTGAGAT GAGGGAGTCG TCGCACCCT
 10
 1201 . V P S S S L G T Q T Y I C N V N
 CCGTGCCCTC CAGCAGCTTG GGCACCCAGA CCTACATCTG CAACGTGAAT
 GGCACGGGAG GTCGTGGAAC CCGTGGGTCT GGATGTAGAC GTTGCACTTA
 StyI
 ~~~~~~  
 15  
 1251 H K P S N T K V D K K V E P K S C .  
 CACAAGCCCA GCAACACCAA GGTGGACAAG AAAGTTGAGC CCAAATCTTG  
 GTGTTGCGGT CGTTGTGGTT CCACCTGTTT TTTCAACTCG GGTTTAGAAC  
 20  
 1301 . D K T H T C P P C P A P E L L G G .  
 TGACAAAAGT CACACATGCC CACCGTGCCC AGCACCTGAA CTCCTGGGGG  
 ACTGTTTTGA GTGTGTACGG GTGGCACGGG TCGTGGACTT GAGGACCCCC  
 BbsI StyI  
 ~~~~~~ ~~~~~~  
 25
 1351 . P S V F L F P P K P K D T L M I
 GACCGTCAGT CTCCTCTTC CCCCCAAAAC CCAAGGACAC CCTCATGATC
 CTGGCAGTCA GAAGGAGAAG GGGGGTTTTG GGTTCCTGTG GGAGTACTAG
 30
 1401 S R T P E V T C V V V D V S H E D .
 TCCCGGACCC CTGAGGTCAC ATGCGTGGTG GTGGACGTGA GCCACGAAGA
 AGGGCCTGGG GACTCCAGTG TACGCACCAC CACCTGCACT CGGTGCTTCT
 BbsI
 ~~~~~~  
 35  
 1451 . P E V K F N W Y V D G V E V H N A .  
 CCCTGAGGTC AAGTTCAACT GGTACGTGGA CGGCGTGGAG GTGCATAATG  
 GGGACTCCAG TTCAAGTTGA CCATGCACCT GCCGCACCTC CACGTATTAC  
 40  
 1501 . K T K P R E E Q Y N S T Y R V V  
 CCAAGACAAA GCCGCGGGAG GAGCAGTACA ACAGCACGTA CCGGGTGGTC  
 GGTTCTGTTT CGGCGCCCTC CTCGTCATGT TGTCGTGCAT GGCCCACCAG  
 45  
 1551 S V L T V L H Q D W L N G K E Y K .  
 AGCGTCCTCA CCGTCCTGCA CCAGGACTGG CTGAATGGCA AGGAGTACAA  
 TCGCAGGAGT GGCAGGACGT GGTCTGACC GACTTACCGT TCCTCATGTT  
 50  
 1601 . C K V S N K A L P A P I E K T I S .  
 GTGCAAGGTC TCCAACAAAG CCCTCCCAGC CCCCATCGAG AAAACCATCT  
 CACGTTCCAG AGGTTGTTTC GGGAGGGTCG GGGGTAGCTC TTTTGGTAGA  
 BsrGI  
 ~~~~~~  
 55
 1651 . K A K G Q P R E P Q V Y T L P P
 CCAAAGCCAA AGGGCAGCCC CGAGAACCAC AGGTGTACAC CCTGCCCCCA
 GGTTTCGGTT TCCCGTCGGG GCTCTTGGTG TCCACATGTG GGACGGGGGT

1701 S R D E L T K N Q V S L T C L V K .
TCCCGGGATG AGCTGACCAA GAACCAGGTC AGCCTGACCT GCCTGGTCAA
AGGGCCCTAC TCGACTGGTT CTTGGTCCAG TCGGACTGGA CGGACCAGTT

5 1751 . G F Y P S D I A V E W E S N G Q P .
AGGCTTCTAT CCCAGCGACA TCGCCGTGGA GTGGGAGAGC AATGGGCAGC
TCCGAAGATA GGGTCGCTGT AGCGGCACCT CACCCTCTCG TTACCCGTCG

10 1801 . E N N Y K T T P P V L D S D G S
CGGAGAACAA CTACAAGACC ACGCCTCCCG TGCTGGACTC CGACGGCTCC
GCCTCTTGTT GATGTTCTGG TGCGGAGGGC ACGACCTGAG GCTGCCGAGG

15 1851 F F L Y S K L T V D K S R W Q Q G .
TTCTTCTCT ACAGCAAGCT CACCGTGGAC AAGAGCAGGT GGCAGCAGGG
AAGAAGGAGA TGTCGTTCGA GTGGCACCTG TTCTCGTCCA CCGTCGTCCC

20 1901 BbsI NsiI
~~~~~  
. N V F S C S V M H E A L H N H Y T .  
GAACGTCTTC TCATGCTCCG TGATGCATGA GGCTCTGCAC AACCACTACA  
CTTGCAAGAG AGTACGAGGC ACTACGTACT CCGAGACGTG TTGGTGATGT

25 1951 SapI PmeI  
~~~~~  
. Q K S L S L S P G K *
CGCAGAAGAG CCTCTCCCTG TCTCCGGGTA AATGAGGGCC CGTTTAAACC
GCGTCTTCTC GGAGAGGGAC AGAGGCCCAT TTACTCCCGG GCAAATTTGG

30 2001 CGCTGATCAG CCTCGACTGT GCCTTCTAGT TGCCAGCCAT CTGTTGTTTG
GCGACTAGTC GGAGCTGACA CGGAAGATCA ACGGTCGGTA GACAACAAAC

35 2051 ~~~~~
pMORPH[®]_Ig_REV 100.0%
CCCCTCCCC GTGCCTTCTT TGACCCTGGA AGGTGCCACT CCCACTGTCC
GGGGAGGGGG CACGGAAGGA ACTGGGACCT TCCACGGTGA GGGTGACAGG

Figure 9: DNA Sequence of Ig kappa light chain expression vector pMORPH®_h_Igκ_1

```

5
      StyI
      ~~~~~
601  TCGCTATTAC CATGGTGATG CGGTTTTTGGC AGTACATCAA TGGGCGTGGA
      AGCGATAATG GTACCACTAC GCCAAAACCG TCATGTAGTT ACCCGCACCT

10
651  TAGCGGTTTG ACTCACGGGG ATTTCCAAGT CTCCACCCCA TTGACGTCAA
      ATCGCCAAAC TGAGTGCCCC TAAAGGTTCA GAGGTGGGGT AACTGCAGTT

701  TGGGAGTTTG TTTTGGCACC AAAATCAACG GGACTTTCCA AAATGTCGTA
      ACCCTCAAAC AAAACCGTGG TTTTAGTTGC CCTGAAAGGT TTTACAGCAT

15
751  ACAACTCCGC CCCATTGACG CAAATGGGCG GTAGGCGTGT ACGGTGGGAG
      TGTTGAGGCG GGGTAACTGC GTTTACCCGC CATCCGCACA TGCCACCCTC

801  GTCTATATAA GCAGAGCTCT CTGGCTAACT AGAGAACCCA CTGCTTACTG
      CAGATATATT CGTCTCGAGA GACCGATTGA TCTCTTGGGT GACGAATGAC

20
      pMORPH®_Ig_FOR 100%
      =====
851  GCTTATCGAA ATTAATACGA CTCACTATAG GGAGACCCAA GCTGGCTAGC
      CGAATAGCTT TAATTATGCT GAGTGATATC CCTCTGGGTT CGACCGATCG

25
      +1      M  V   L  Q  T   Q  V  F   I  S  L  L   L  W  I
      StyI
      ~~~~~
901  GCCACCATGG TGTTGCAGAC CCAGGTCTTC ATTTCTCTGT TGCTCTGGAT
      CGGTGGTACC ACAACGTCTG GGTCCAGAAG TAAAGAGACA ACGAGACCTA

30
      BbsI
      ~~~~~

      +1      S  G  A   Y  G  D  I   V  M  I   K  R  T   V  A  A
      EcoRV
      ~~~~~
      BsiWI
      ~~~~~
951  CTCTGGTGCC TACGGGGATA TCGTGATGAT TAAACGTACG GTGGCTGCAC
      GAGACCACGG ATGCCCCTAT AGCACTACTA ATTTGCATGC CACCGACGTG

35

40
      +1  P  S  V  F   I  F  P   P  S  D  E   Q  L  K   S  G  T
1001 CATCTGTCTT CATCTTCCCG CCATCTGATG AGCAGTTGAA ATCTGGAACT
      GTAGACAGAA GTAGAAGGGC GGTAGACTAC TCGTCAACTT TAGACCTTGA
      BbsI
      ~~~~~

45

```

5
10
15
20
25
30
35

+1 A S V V C L L N N F Y P R E A K V
1051 GCCTCTGTTG TGTGCCTGCT GAATAACTTC TATCCCAGAG AGGCCAAAGT
CGGAGACAAC ACACGGACGA CTTATTGAAG ATAGGGTCTC TCCGGTTTCA

+1 Q W K V D N A L Q S G N S Q E S
1101 ACAGTGAAG GTGGATAACG CCCTCCAATC GGGTAACTCC CAGGAGAGTG
TGTCACCTTC CACCTATTGC GGGAGGTTAG CCCATTGAGG GTCCTCTCAC

+1 V T E Q D S K D S T Y S L S S T L
1151 TCACAGAGCA GGACAGCAAG GACAGCACCT ACAGCCTCAG CAGCACCCTG
AGTGTCTCGT CCTGTCTGTC CTGTCTGTGGA TGTCGGAGTC GTCGTGGGAC

+1 T L S K A D Y E K H K V Y A C E V
BlpI
~~~~~  
1201 ACGCTGAGCA AAGCAGACTA CGAGAAACAC AAAGTCTACG CCTGCGAAGT  
TGCGACTCGT TTCGTCTGAT GCTCTTTGTG TTTCAGATGC GGACGCTTCA

+1 T H Q G L S S P V T K S F N R G  
1251 CACCCATCAG GGCCTGAGCT CGCCCGTCAC AAAGAGCTTC AACAGGGGAG  
GTGGGTAGTC CCGGACTCGA GCGGGCAGTG TTTCTCGAAG TTGTCCCCTC

+1 E C \*  
PmeI  
~~~~~  
1301 AGTGTTAGGG GCCCGTTTAA ACCCGCTGAT CAGCCTCGAC TGTGCCTTCT
TCACAATCCC CGGGCAAATT TGGGCGACTA GTCGGAGCTG ACACGGAAGA

=
1351 AGTTGCCAGC CATCTGTTGT TTGCCCCTCC CCCGTGCCTT CCTTGACCCT
TCAACGGTCG GTAGACAACA AACGGGGAGG GGGCACGGAA GGAAGTGGGA

pMORPH®_Ig_REV 100%
=====

Figure 10: DNA Sequence of HuCAL® Ig lambda light chain vector pMORPH®_h_Igλ_I

```

                StyI
            ~~~~~~
5      601  TCGCTATTAC CATGGTGATG CGGTTTTGGC AGTACATCAA TGGGCGTGGA
          AGCGATAATG GTACCACTAC GCCAAAACCG TCATGTAGTT ACCCGCACCT

          651  TAGCGGTTTG ACTCACGGGG ATTTCCAAGT CTCCACCCCA TTGACGTCAA
          ATCGCCAAAC TGAGTGCCCC TAAAGGTTCA GAGGTGGGGT AACTGCAGTT

10     701  TGGGAGTTTG TTTTGGCACC AAAATCAACG GGACTTTCCA AAATGTCGTA
          ACCCTCAAAC AAAACCGTGG TTTTAGTTGC CCTGAAAGGT TTTACAGCAT

          751  ACAACTCCGC CCCATTGACG CAAATGGGCG GTAGGCGTGT ACGGTGGGAG
          TGTTGAGGCG GGGTAACTGC GTTTACCCGC CATCCGCACA TGCCACCCTC

          801  GTCTATATAA GCAGAGCTCT CTGGCTAACT AGAGAACCCA CTGCTTACTG
          CAGATATATT CGTCTCGAGA GACCGATTGA TCTCTTGGGT GACGAATGAC

20     851  GCTTATCGAA ATTAATACGA CTCACTATAG GGAGACCCAA GCTGGCTAGC
          CGAATAGCTT TAATTATGCT GAGTGATATC CCTCTGGGTT CGACCGATCG

                pM_Ig_FOR 100.0%
            =====
                NheI
            ~~~~~~

25     +1      M  A  W  A  L  L  L  L  T  L  L  T  Q  G  T
          StyI
          ~~~~~~

          901  GCCACCATGG CCTGGGCTCT GCTGCTCCTC ACCCTCCTCA CTCAGGGCAC
          CGGTGGTACC GGACCCGAGA CGACGAGGAG TGGGAGGAGT GAGTCCCGTG

30     +2      T  V  L  G  Q
          +1  G  S  W  A  D  I  V  M  H  E  V
          BamHI      EcoRV      HpaI      StyI
          ~~~~~~

35     951  AGGATCCTGG GCTGATATCG TGATGCACGA AGTTAACCGT CCTAGGTCAG
          TCCTAGGACC CGACTATAGC ACTACGTGCT TCAATTGGCA GGATCCAGTC

          +2  P  K  A  A  P  S  V  T  L  F  P  P  S  S  E  E  L
          StyI
          ~~~~~~

40     1001  CCCAAGGCTG CCCCTCGGT CACTCTGTTC CCGCCCTCCT CTGAGGAGCT
          GGGTTCCGAC GGGGGAGCCA GTGAGACAAG GCGGGGAGGA GACTCCTCGA

          +2  Q  A  N  K  A  T  L  V  C  L  I  S  D  F  Y  P
45     1051  TCAAGCCAAC AAGGCCACAC TGGTGTGTCT CATAAGTGAC TTCTACCCGG
          AGTTCGGTTG TTCCGGTGTG ACCACACAGA GTATTCACTG AAGATGGGCC

```

5 +2 G A V T V A W K G D S S P V K A G
1101 GAGCCGTGAC AGTGGCCTGG AAGGGAGATA GCAGCCCCGT CAAGGCGGGA
CTCGGCACTG TCACCGGACC TTCCCTCTAT CGTCGGGGCA GTTCCGCCCT

10 +2 V E T T T P S K Q S N N K Y A A S
1151 GTGGAGACCA CCACACCCTC CAAACAAAGC AACAAACAAGT ACGCGGCCAG
CACCTCTGGT GGTGTGGGAG GTTTGTTCG TTGTTGTTCA TGCGCCGGTC

+2 S Y L S L T P E Q W K S H R S Y
1201 CAGCTATCTG AGCCTGACGC CTGAGCAGTG GAAGTCCCAC AGAAGCTACA
GTGCATAGAC TCGGACTGCG GACTCGTCAC CTTCAGGGTG TCTTCGATGT

15 +2 S C Q V T H E G S T V E K T V A P
BbsI
~~~~~  
1251 GCTGCCAGGT CACGCATGAA GGGAGCACCG TGGAGAAGAC AGTGGCCCCT  
CGACGGTCCA GTGCGTACTT CCCTCGTGGC ACCTCTTCTG TCACCGGGGA


20 +2 T E C S \*  
PmeI  
~~~~~  
1301 ACAGAAATGTT CATAGGGGCC CGTTTAAACC CGCTGATCAG CCTCGACTGT
TGTCTTACAA GTATCCCCGG GCAAATTTGG GCGACTAGTC GGAGCTGACA
pM_Ig_REV 100%
=====

25 1351 GCCTTCTAGT TGCCAGCCAT CTGTTGTTTG CCCCTCCCCC GTGCCTTCCT
CGGAAGATCA ACGGTCGGTA GACAACAAAC GGGGAGGGGG CACGGAAGGA
pM_Ig_REV 100.0%
=====

30

Fig. 11: Agonistic activities

5



10

Figure 12: Specificity ELISA

5




Fig. 13: Cytotoxicity towards CD34+/CD38+ progenitor cells




Fig. 14: ADCC with different cell-lines

| Cellline | Culture Collection | Origin | Expression [MFI] | Max: specific killing [%] in ADCC ³⁸ | | | |
|--------------------|---------------------------------|------------------|---------------------|---|-------|-------|------|
| | | | | Mab#1 | Mab#2 | Mab#3 | PG |
| RPMI 8226 | ATCC CCL-155 | MM | 405.71 | 56 | 58 | 54 | 46 |
| KMS-12-BM | DSMZ ACC551 | MM | 142.29 | 26 | 32 | 30 | 34 |
| NCI-H929 | ECACC95050415 | MM | 45.01 | 68 | 73 | 38 | 54 |
| OPM-2 | DSMZ ACC50 | MM | 37.99 | 6 | 13 | 3 | 7 |
| U-266 | ECACC85051003 | MM | 26.14 | 17 | 14 | 12 | 16 |
| KMS-11 | Namba et al., 1989 ^b | MM | 26.81 ^a | 22 | 30 | 26 | 28 |
| JVM-13 | DSMZACC19 | CLL | 463.93 | 11 | 20 | 12 | 15 |
| JVM-2 | DSMZACC12 | CLL | 140.84 | 22 | 28 | 10 | 24 |
| CCRF-CEM | ECACC85112105 | ALL | 301.46 | 24 | 29 | 20 | 22 |
| Jurkat | DSMZ ACC282 | ALL | 202.99 | 7 | 8 | 13 | 12 |
| AML-193 | DSMZ ACC549 | AML | 62.69 ^d | 33 | 26 | 39 | 33 |
| OCI-AML5 | DSMZ ACC247 | AML | 207.55 ^d | 20 | 21 | 16 | 26 |
| NB-4 | DSMZ ACC207 | AML | 164.7 ^d | 36 | 38 | 32 | 37 |
| THP-1 | DSMZ ACC16 | AML | 34.41 | 64 | 59 | 38 | 43 |
| HL-60 ^d | DSMZ ACC3 | AML | 18.43 ^d | 29 | 35 | 29 | 29 |
| Raji | Burkitt's Lymph. | Burkitt's lymph. | n.d. | 53 | 62 | 48 | n.d. |

Fig. 15: ADCC with MM-samples

| Antibodies | Mab#1 | Mab#2 | Mab#3 | PG |
|--------------------------------------|-------------|-------------|-------------|-------------|
| Parameters: | | | | |
| MM samples: EC50 [nM] ^a : | 0.116-0.202 | 0.006-0.185 | 0.027-0.249 | 0.282-0.356 |
| MM samples: Max spec. killing [%] | 13.1 - 61.6 | 16.2 - 57.9 | 13.6 - 36.0 | 15.5 - 49.5 |




Fig. 16: Treatment of human myeloma xenograft with MOR03080


Fig. 17: Cross-reactivity FACS analysis


Figure 18 : CD38 cross-linking with Raji cells


Figure 19: CDC assay with hCD38 CHO-transfectants

Figure 20: ADCC assay with primary multiple myeloma samples